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Abstract 
Rapid and potent expression of the pro-inflammatory cytokine, interleukin (IL)-1β, is a 
unique characteristic of macrophages. Enhancers are distal regulatory elements that promote 
gene expression in a cell-type specific manner. PU.1 is a lineage-determining transcription 
factor that regulates myeloid-specific genes by activating distal enhancers. To date, how 
macrophages rapidly and potently express IL-1β is not well understood. This study identifies 
a potential enhancer of IL-1β, and how PU.1 regulates its activity state in macrophages and 
non-myeloid cells. Enhancers are demarcated by unique histone modifications: high in 
H3K27Ac and H3K4me1, and low in H3K4me3. Based on the ChIP-seq data available from 
the ENCODE database, I found a genomic region located ~10 kbs upstream of the IL-1β TSS 
with these histone signatures. I hypothesize that the genomic region is an enhancer that 
regulates the expression of IL-1β mRNA in a PU.1-dependent manner in murine 
macrophages. A putative enhancer RNA (eRNA) was transcribed from the enhancer, and 
knock-down of the eRNAs with antisense oligonucleotides inhibited IL-1β production. 
Furthermore, through chromatin conformation capture (3C) analysis, enhancer-promoter 
interactions were detected in macrophages stimulated with the bacterial cell component 
lipopolysaccharide (LPS), confirming that the genomic element was an IL-1β enhancer. 
Overexpression of PU.1 in non-myeloid B16-BL6 cells induced IL-1β enhancer-promoter 
interaction, and promoted the expression of IL-1β mRNA and eRNAs upon LPS exposure. 
Enhancer knock-out by the CRISPR-Cas9 system reduced IL-1β expression in these cells. In 
summary, this study indicates that PU.1 alters the chromatin architecture which allows rapid 
and potent expression of IL-1β eRNAs and mRNA. 
Keywords 
Macrophages, Interleukin (IL)-1β, gene regulation, enhancers, enhancer RNAs, lineage-
determining transcription factors, PU.1, chromatin architecture, chromatin conformation 
capture 
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CHAPTER 1 
1 INTRODUCTION 
1.1 Macrophage Differentiation 
Macrophages are effector cells that have essential homeostatic and immunological roles 
in humans [1,2]. They are best known as sentinel innate immune cells that are responsible 
for detecting and killing foreign pathogens via phagocytosis [1-3]. Additionally, 
macrophages partake in generating rapid immune responses against invading 
microorganisms by producing various pro-inflammatory cytokines [4,5]. In addition to 
their immunological roles, their involvement in maintaining tissue homeostasis also 
needs recognition. Contribution to tissue and organ homeostasis is exemplified by their 
function as a janitorial cell that removes erythrocytes, cellular debris, and apoptotic and 
senescent cells [1]. Due to their anatomical location and physiological function, 
macrophages are often classified as a member of the mononuclear phagocytosis system 
(MPS) along with monocytes and dendritic cells [6]. Within this mononuclear phagocytic 
lineage, tissue-resident macrophages are considered as terminally differentiated cells that 
originate from circulating monocytes [2]. As circulating monocytes migrate into various 
tissues from the bloodstream, they undergo differentiation to become resident 
macrophages and perform specialized functions according to the microenvironment 
[2,5,7]. For example, osteoclasts are primarily involved in bone remodeling, and the 
absence of these specialized macrophages can result in osteoporosis and osteopetrosis 
[2,7]. Alveolar macrophages equipped with pattern recognition receptors (PRRs) and 
scavenger receptors on the surface are necessary for efficient clearance of 
microorganisms in the lung [7]. Thus, cells of the MPS, particularly macrophages, exhibit 
remarkable heterogeneity and plasticity [5,7]. Recently, the Immunological Genome 
(ImmGen) project (https://www.immgen.org/) has been launched to address whether or 
not the phenotypic and functional variance of tissue-resident macrophages are the result 
of unique gene expression profiles [8]. Analyses of the gene expression patterns of 
several populations of macrophages including peritoneal, splenic, and alveolar 
macrophages have shown that the expression levels of only a few selective genes, such as 
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MerTK, Toll-like receptor (TLR) 4, TLR7, TLR8, and TLR13, remained uniform across 
all populations [8]. These data indicated that the ability of macrophages to efficiently 
adapt to their surroundings and generate cell-type specific responses against external 
stimuli is a reflection of their variance in gene expression profiles.  
1.1.1 Classically-activated vs. alternatively-activated macrophages 
Macrophages express diverse classes of surface receptors such as PRRs, scavenger 
receptors, phosphatidyl serine receptors, integrins, and complement receptors that are 
required for their function [9]. Expression of such wide range of surface receptors allows 
macrophages to exhibit remarkable plasticity in nature. Based on their characteristics in 
producing inflammatory and immunoregulatory responses, a binary classification system 
is often used to distinguish macrophage activation states: classically-activated (M1) and 
alternatively-activated (M2) macrophages [1,5,10,11]. Microbial products such as 
lipopolysaccharide (LPS), and the inflammatory cytokines interferon (IFN)-γ, and tumor 
necrosis factor (TNF)-α induce macrophages to polarize toward M1 macrophages. M1 
macrophages promote inflammation by secreting pro-inflammatory cytokines such as 
interleukin (IL)-1β, IL-6, and IL-23 and anti-microbial molecules such as reactive oxygen 
species (ROS) and nitrogen radicals [1,5,10]. In contrast, exposure of macrophages to IL-
4, and IL-13 generates M2 macrophages that induce anti-inflammatory responses or have 
wound healing capabilities [1,5,10]. The contrasting characteristics of M1 and M2 
macrophages are likely the result of unique gene expression profiles. Despite many genes 
that are co-upregulated or co-downregulated in macrophages of both activity states, there 
are multiple genes that are exclusively induced in one type of macrophages while 
suppressed in the other [11]. For example, it has been reported that N-formyl peptide 
receptor 2 (Fpr2) and cluster of differentiation 38 (CD38) are greatly enhanced in M1 
macrophages [11]. Fpr2 is a G-protein coupled receptor that recognizes bacteria-derived 
N-formyl methionyl peptides, resulting in increased chemotaxis and ROS production by 
macrophages; whereas, CD38 is a glycoprotein that catalyzes the synthesis of key 
messengers of calcium signaling, cADP-ribose and ADP-ribose, from NAD+ [11]. On the 
other hand, early growth response protein 2 (Egr2) is a gene that tends to be specifically 
upregulated in M2 macrophages [11]. Egr2 is a transcription factor (TF) that is closely 
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linked to cell proliferation, tumour suppression, and peripheral nerve myelination [12]. 
This particular TF also induces the generation of macrophage colony-stimulating factor 
(M-CSF) receptor, which is involved in the generation of anti-inflammatory macrophages 
[12,13].  
1.1.2 Signaling pathway activated by LPS 
LPS is a main constituent of the outer membrane of Gram-negative bacteria. LPS sledded 
from bacteria that enter the bloodstream of the host are detected by LPS-binding proteins 
(LBPs) [14,15]. LBP traffics LPS to CD14, which functions as a co-receptor that presents 
LPS monomers to the TLR4 and lymphocyte antigen 96 (MD2) complex [14,16,17]. 
Binding of phosphate and acyl groups of LPS to TLR4 and MD2, respectively, induces 
the dimerization of TLR4-MD2 complex that triggers intracellular signaling cascades 
through the toll/IL-1 receptor (TIR) domain [14]. TIR recruits one of the TIR containing 
adaptor proteins known as myeloid differentiation factor (MyD) 88, through interacting 
with another TIR containing adaptor protein, MyD88-adapter-like (Mal) [18]. Interaction 
between TLR4s and MyD88 initiates a cascade of signaling events that activates nuclear 
factor (NF)-κB [14]. At steady state, NF-κB is localized in the cytoplasm due to the 
cytosolic protein inhibitor κB (IκB) [19]. The signal transduction triggered by LPS causes 
degradation of IκB that leads to translocation of NF-κB to the nucleus and initiation of 
transcription [14]. In addition, TLR4 activates the MyD88-independent pathway, which 
is mediated by another TIR motif containing adaptors, known as TIR domain-containing 
adapter inducing interferon (TRIF) and TRIF-related adapter molecule (TRAM). The 
signaling cascade activated by these adaptors leads to the activation of NF-κB, IFN 
regulatory factor (IRF) 3 and IRF7 [17,20]. IRF3 and 7 promote the synthesis of IFN-α 
and -β that bind to their respective cognate receptors on the macrophages [20]. Activation 
of IFN receptors triggers the Janus kinases (JAKs)/ Signal transducer and activator of 
transcription (STAT) signaling cascade that induces expression of genes involved in anti-
viral responses and caspase-11 [20,21]. Caspase-11 mediates NLRP3-induced cleavage 
of pro-caspase-1 into caspase-1 [21]. Caspase-1 is also known as the IL-1β-converting 
enzyme that converts biologically inactive pro-IL-1β to its active form [22]. 
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1.2 IL-1β 
The IL-1 family of cytokines are crucial elements of the innate immune system that can 
either initiate or suppress inflammation [22]. It comprises 11 members, which include IL-
1α, -1β, -1Ra, -18, -1H4, -1H2, -1ε, -1HY2, -33, FIL1δ, and FIL1ε, with diverse roles in 
immune responses. For example, IL-1α and -1β are potent pro-inflammatory cytokines; 
whereas IL-1Ra, FIL1δ, and IL-1H4 have anti-inflammatory roles [22,23]. Amongst the 
IL-1 cytokines, IL-1β has been studied most thoroughly, and many reports highlight its 
role in various cellular processes such as cell differentiation, autophagy and apoptosis, 
and immune activation through T lymphocytes [24-27]. Despite the importance of IL-1β 
in the innate immune system, failure to control the intensity and duration of its expression 
can cause the development of autoinflammatory diseases, as it is closely associated with 
local and systemic inflammation [22,28]. Autoinflammatory diseases are a class of 
clinical disorders that arise due to dysregulation of the innate immune system, often 
resulting in chronic inflammation [22,29]. Most notably, familial cold autoinflammatory 
syndrome (FCAS), gout, type 2 diabetes, and Muckle-Wells syndrome are examples of 
IL-1β-associated autoinflammatory diseases [22,29]. Thus, IL-1β serves as a good 
therapeutic target to treat atherosclerosis and type 2 diabetes, as well as other 
inflammatory diseases [30-32].  
1.3 Gene Regulation 
1.3.1 Regulatory Elements 
It is well established that each cell has a unique gene expression profile that determines 
its phenotype and allows to perform biological functions. Also the expression of genes 
must be tightly controlled, as dysregulation can give rise to various diseases. There are 
multiple regulatory elements that corporately regulate transcription. For example, core 
promoters are generally defined as nucleosome-depleted and DNaseI hypersensitive 
regions that encompass multiple elements such as the transcription start site (TSS) and 
the TATA box [33,34]. These proximal regulatory entities serve as the platform for the 
basal transcriptional machinery and the designated site of pre-initiation complex 
assembly [33,34]. Ultimately, promoters function in concert with distal regulatory 
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elements that either suppress or activate transcription of the target gene [35]. A large 
portion of mammalian genome is non-coding regions that were once considered as ‘junk 
sequences’ [36]. However, these non-coding regions contain functional distal regulatory 
elements which are now regarded as key players of gene regulation. Enhancers are distal 
regulatory elements that positively regulate and enhance transcription of cognate genes in 
a spatiotemporal manner [33]. Similar to promoters, enhancers also recruit the 
transcriptional machinery and produce transcripts commonly referred to as enhancer 
RNAs (eRNAs) [37]. In addition, silencers and insulators are regulatory elements that 
serve as negative regulators of gene expression [33]. Within the genome, silencers, which 
are docking sites for repressors, can be positioned either away from or within proximal 
promoters [33]. Insulators also serve as negative regulatory elements that are renowned 
for their two functions: barrier function (prevent decompaction of chromatin) and 
enhancer blocking [36,38]. Notably, insulators can block the activity of enhancers by 
preventing the formation of inter- and intra-chromosomal interaction between enhancers 
and irrelevant genes [36]. Altogether, the interplay of positive and negative regulatory 
elements as well as various transcription factors dictate the gene expression profile of a 
cell. 
1.3.2 Epigenetics 
Gene regulation is not limited to the activity of regulatory elements; but also controlled 
by epigenetics, which is defined as inheritable regulation of gene expression without 
changes in the DNA sequence [39]. Amongst many epigenetic processes, DNA 
methylation is one of the most thoroughly studied [39]. Generally, DNA methylation is 
known to have a robust inverse relationship with chromatin accessibility [40]. 
Methylation of DNA is mediated by DNA methyltransferases (DNMTs), a family of 
proteins that transfers methyl groups to cytosine in CpG dinucleotides (cytosine directly 
linked to guanosine via phosphodiester bond) in mammals [39,41]. Specifically, methyl 
groups are added to the C5 position of cytosine, forming 5-methylcytosine (5mC) [39]. It 
is widely accepted that 5mC is a methylation marker that has a repressive effect on gene 
expression [41,42]. For example, Hashimoto et al. demonstrated that chemical treatment 
(IL-1β or TNF-α ± oncostatin M or 5-aza-deoxycytidine) of human articular 
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chondrocytes induced the production of IL-1β mRNA and protein [43]. Intriguingly, they 
observed a significant reduction in the methylation of CpG sites in the promoter of IL-1β 
[43], suggesting that the methylation status of the gene is an epigenetic marker that 
regulates its production. Likewise, the methylation status of enhancers has also been 
shown to contribute in gene regulation; and ultimately be involved in disease progression 
and cancer development [44]. Monomethylation of histone (H) 3 lysine (K) 4 
(H3K4me1), a unique chromatin signature of enhancers, is associated with DNA 
hypermethylation [45]. In addition, DNA methylation negatively correlates with 
acetylation of H3K27 (H3K27Ac), which demarcates active enhancers, [45]. Specifically, 
hypermethylation of DNA results in diminished levels of H3K27Ac at enhancers [45, 
46], and essentially reduces the activity of these distal regulatory elements [47]. There are 
currently two mechanisms suggested for DNA demethylation. In passive DNA 
demethylation, loss of methyl groups occurs in cell replication-dependent manner, and 
daughter cells inherit less methylated DNA due to inhibition of DNMTs [41,48,49,50]. 
Active DNA demethylation occurs independently of cell replication and is a more rapid 
process that involves direct removal of the methyl groups. Initially, ten-eleven 
translocation (TET) protein converts 5mC to 5-hydroxymethylcytosine (5hmC), an 
intermediate form of oxidized 5mC [49]. 5hmC can be further oxidized into metabolites 
such as 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) by TET proteins, in which 
the resulting products are fixed via base excision repair facilitated by thymine DNA 
glycosylase [48,51,52].  
Post-translational modification (PTM) of histones is another notable epigenetic 
mechanism that is essential for gene regulation [44]. Histones are positively charged 
nuclear proteins that closely associate with negatively charged DNA to form chromatin 
[53]. Initially, 147 base pairs of DNA are wrapped around histone octamers that consist 
of two H2A-H2B dimers and one H3-H4 tetramer [53]. Supercoiling of DNA around the 
histone octamer forms the basic unit of DNA compaction, nucleosomes [53,54]. The N-
termini of H2B, H3, H4, and C-terminus of H2A, commonly referred to as histone tails, 
tend to protrude from nucleosomes, and are prone to various PTMs such as methylation, 
acetylation, phosphorylation, ubiquitination, SUMOylation, ADP ribosylation, and 
deamination [54]. Formation of nucleosomes for the purpose of DNA compaction is 
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undoubtedly important; however, such tight packaging of the DNA can limit accessibility 
by various TFs and interfere with proper gene expression [55]. Thus, remodeling of 
nucleosomes mediated by PTMs such as methylation, acetylation, and phosphorylation is 
necessary to overcome such structural complications [55].  
Histone tails are enriched in positively charged K and arginine (R), which are subject to 
methylation [55,56]. Histone methylation involves the transfer of methyl groups from S-
adenosylmethionine to the ε-amino group of K and ϖ-guanidino group of R by lysine 
methyltransferases and arginine methyltransferases, respectively [56]. Although both 
amino acids can be methylated, K4, 9, 27, and 36 of H3 and K20 of H4 are considered as 
the most common substrates for methylation [57]. Lysine residues can be methylated to 
varying degrees (mono-, di-, tri-), which affect the hydrophobic and steric properties of 
the amino acid [58]. The three degrees of methylation marks at specific K residues serve 
as docking sites for various effector proteins, and can dictate the role of lysines as either 
activators or repressors of gene expression [58]. For example, monomethylation of H3K4 
H3K4, H3K36, and H3K79 are associated with transcriptional activation, whereas higher 
degrees of methylation at H3K9, H3K27, and H4K20 are involved in repressive gene 
expression [59]. Interestingly, methylated lysine residues may have further contributions 
in gene regulation by serving as specific markers of proximal and distal regulatory 
elements. For example, combination of H3K4me1 and H3K4me3 are characteristics that 
are considered when defining proximal promoters and distal enhancers, as unique ratios 
of these epigenetic signatures are conserved at these regulatory elements across the 
genome [47,60,61]. High and low levels of H3K4me1 and H3K4me3 (H3K4me1hi, 
H3K4me3low) are recruited at distal enhancers while the inverse ratio (H3K4me1low, 
H3K4me3hi) of these histone modifications are observed at proximal promoters [60,61]. 
Histone acetylation is a reversible PTM that correlates with active gene expression by 
promoting the formation of euchromatin and increasing DNA accessibility [62]. Unlike 
histone methylation, acetylation of K residues neutralize the charge of the histone tails 
[63]. Acetylation-mediated loss of charge can disrupt the interaction between histones 
and DNA, essentially causing the chromatin to take on an ‘open’ conformation [44,63]. 
The transfer of acetyl group from acetyl Coenzyme A (acetyl-CoA) to the ε-amino group 
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of K is catalyzed by histone acetyltransferases (HATs) [63]. HATs are multisubunit 
protein complexes that can be classified as either cytoplasmic proteins that acetylate 
newly synthesized histones prior to nuclear translocation or nuclear proteins that 
promotes addition of acetyl groups to histone tails [63]. There are five subclasses of 
HATs: general control nonderepressible 5 (Gcn5)-related acetyltransferases (GNATs); 
MOZ, Ybf2/Sas3, Sas2, Tip60 (MYST)-related HATs; p300/CREB-binding protein 
(CBP) HATs; general transcription factor HATs (TFIID subunit TAF250); nuclear 
hormone-related (steroid receptor coactivator 1/3) HATs [64]. Although the HAT domain 
responsible for interacting with CoA is conserved in all subclasses, substrate specificity 
of HATs still varies between and within subclasses, as each HAT complex comprises 
distinct combinations of domains and subunits [64]. For example, GNATs that contain 
Gcn5 alone preferentially acetylates H3K14, while the accessory protein, Ada, modifies 
H3K9, 14, and 18 [64]. Similar to histone methylation marks, acetylation of specific K 
residues can also be utilized as markers of regulatory elements. p300/CBP HATs are 
homologous proteins that serve as transcriptional co-activators [65]. These histone 
modifiers are often recruited to enhancers, and can acetylate all four types of histones 
[65]. Specifically, previous studies reported that p300/CBP are capable of catalyzing the 
acetylation of H3K27 (H3K27Ac), a unique marker of active enhancers [66,67].   
The level of histone acetylation is maintained by the interplay of HATs and histone 
deacetylases (HDACs) [63]. HDACs are responsible for the removal of acetyl group from 
the K residues, resulting in hypoacetylation of histone tails that strengthens the 
interaction between histones and DNA [63]. HDACs can be classified into either the 
classical (Zn2+-dependent) or SIR2 (silent information regulator 2; NAD+-dependent) 
families [63]. The classical HDACs are subdivided into Class I (HDAC 1, 2, 3, 8), Class 
II (HDAC 4-7, 9, 10), and Class IV (HDAC 10) [63]. These metal-dependent 
deacetylases have activation sites that require Zn2+ as the cofactor [63]. Class I HDACs 
are primarily localized and active in the nucleus, whereas most class II HDACs exist 
within the cytoplasm [63,68]. Although HDAC10 (class IV) is the least studied amongst 
all HDACs, the current understanding is that it has roles in both nuclear and cytoplasmic 
compartments [68]. There are 7 Sir2 family members (SIRT1-7) that belong in class III 
of deacetylases [68]. Sir2 HDAC-mediated deacetylation of K residues involves the 
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transfer ADP-ribose from NAD+ to acetyllysine [68]. This particular class of HDACs are 
distributed throughout the entire cell and are localized in the nucleus, cytoplasm, as well 
as mitochondria [68]. In general, HDACs do not repress gene expression alone, but rather 
work in concert with other repressor proteins like DNA methyltransferases [63].   
1.3.3 Chromatin Organization 
All cellular activities that govern physiological and homeostatic events in the body are 
dictated by the genetic information stored in the DNA. The entire human genome, which 
can span 2 meters in length, must be tightly organized in order to be packed in the 
nucleus of a single cell (Fig. 1.1). The formation of nucleosomes is the initial step of 
DNA compaction that reduces the length of the genome by approximately 7-fold [54]. 
Then, the chromosomes are segregated into distinct chromosome territories, which allow 
intra-chromosomal interactions to form while communication between chromosomes 
becomes less preferred [54,69]. Within the chromosome territories, the chromosomes are 
partitioned into either open (“A”) or closed (“B”) regions [54]. The open compartment is 
occupied by DNA segments that are enriched in genes, regulatory elements, and various 
features that mark active transcription, whereas closed compartments consist of 
transcriptionally repressive genomic regions [54]. The DNA in A and B compartments 
are then further segregated into topologically associating domains (TADs), which 
organize co-expressed genes into distinct regions [54,70]. Despite being positioned in 
different chromosomes, genes within TADs can be subjected to transcriptional activation 
mediated by trans-acting enhancers that exist in the same TADs via intermolecular 
interactions [54]. The DNA segments in TADs tend to be on average ~800 kb in length, 
and these genomic entities are retained throughout cell differentiation [70-72]. 
Interestingly, the nuclear positions of these TADs tend to be conserved across species 
including humans, mouse, and fruit flies [71]. Finally, TADs can be partitioned into sub-
TADs, in which these subdomains tend to vary between cell types [54].  
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Figure 1.1. Packaging of the genome in the nucleus occurs in a hierarchical manner. 
At the top of the hierarchy, chromosomes are initially organized into distinct regions in 
the nuclear space (chromosome territories – different coloured regions in the nucleus), 
where the genome is further partitioned into transcriptionally active (A) or repressive (B) 
compartments. Within each compartment, TADs (red circular region) and sub-TADs 
(small green circular regions within TADs) are formed, allowing chromatin looping-
mediated interaction between regulatory elements such as enhancers, silencers, and 
insulators with the promoters of target genes to occur. 
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1.4 Distal regulatory element: Enhancers 
Enhancers are cis- and trans-acting regulatory elements that engage with promoters over 
long distances to promote gene transcription in a cell-type specific manner [42,73,74]. As 
above-mentioned, unique gene expression profiles are determined by combinatory 
activities of different regulatory elements [75]. Recent studies showed that more than 1 
million putative enhancers, which greatly exceeds the number of coding genes, have been 
identified in the human genome [76,77]. These enhancers are hypersensitive to DNases, 
indicating euchromatin status of their chromatin landscapes. The lineage-determining 
transcription factors (LDTFs) are crucial proteins that bind specific motifs within 
enhancers and promote a shift in chromatin architecture from heterochromatin to 
euchromatin via ATP-dependent nucleosome remodelers [42,73,74,76]. Subsequently, 
co-activators, p300/CBP, are recruited to the readily accessible enhancers [42,74]. These 
histone modifiers induce epigenetic reprogramming of nucleosomes that flank the 
enhancer domains [73]. When enhancers are activated, TFs and RNA polymerase II 
(RNAPII) are recruited to the enhancers, resulting in dynamic transcription of eRNAs 
[42,73,77-81]. However, the mechanisms of how enhancers promote gene transcription 
are not fully understood. It is speculated that enhancers promote transcription by 
recruiting the pre-initiation complex and releasing RNAPII from the promoter to move 
along the DNA [74]. 
1.4.1 Epigenetic signatures of enhancers 
DNA segments with chromatin signatures H3K4me1hi and H3K4me3low were originally 
defined as enhancers, whereas higher levels of H3K4me3 compared to H3K4me1 were 
recruited at active promoters [42,60,82]. Dissimilar to the invariant binding patterns of an 
insulator protein CCCTC-binding factor (CTCF), the locations of H3K4me1-marked 
enhancers are different across many cell types [60]. Additionally, cells also display 
highly distinct distribution patterns of DNase-hypersensitive and p300-binding sites 
[60,83]. These results indicate that the association of nucleosome-depleted genomic 
regions with H3K4me1 and p300 is a marker for cell-type specific enhancers. It was also 
shown that H3K4me1 is deposited at potential enhancers prior to nucleosomal depletion 
and enrichment of H3K27Ac [84]. In some cases, H3K4me1 remains bound to enhancers 
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following the dissociation of H3K27Ac, a unique histone modification of active 
enhancers [85]. The difference in the dynamics of these histone modifications suggest 
that H3K4me1 is an epigenetic marker of both active and poised enhancers [60,86].  
As previously mentioned, co-activators like p300 and CBP are HATs that are recruited to 
enhancers and acetylate H3K27 [42,66,67,87]. Further studies confirmed that H3K27Ac 
demarcates active enhancers [82,85]. HAT-mediated acetylation of H3K27 plays a 
central role in promoting the release of RNAPII. Upon acetylation, bromodomain-
containing protein (Brd) 4, a member of the bromodomain and extra terminal domain 
(BET) family of proteins, binds to acetylated K residues of histone H3 and H4 [88,89]. 
The association of Brd4 with acetylated histones is followed by the recruitment of the 
positive transcription elongation factor (P-TEFb) and the Mediator complex [90]. Brd4 
converts P-TEFb into an active form that leads to the phosphorylation of negative 
elongation factor (NELF) complex and DRB sensitivity inducing factor (DSIF), which 
directly interact with RNAPII to hold the polymerase at the promoter region [91,92]. 
Furthermore, P-TEFb also phosphorylates Serine 2 (Ser2) of carboxy terminal domain 
(CTD) of RNAPII, a modification that indicates the transition of a polymerase from the 
pause to the elongation phase [91,93]. Kaikkonen et al. demonstrated this phenomenon in 
macrophage enhancers as elevated levels of Ser2P RNAPII are observed near the 
nucleosome free regions post stimulation with the TLR4 agonist Kdo2-Lipid A [91]. 
Therefore, a method in identifying active enhancers is through examining the H3K4me1, 
H3Kme3, and H3K27Ac markers.  
1.4.2 Lineage-determining transcription factors of macrophage 
enhancers 
The plastic nature of macrophages that allows the cells to achieve diverse functional 
states in response to various microenvironments is mediated by enhancers, which 
promote the expression of specific genes [94]. Amongst several hematopoietic TFs, PU.1 
plays a central role in the development of macrophages and B cells [95]. PU.1 is a 
member of the Ets family of proteins that specifically recognize and bind to purine-rich 
motifs of DNA [96,97]. PU.1 has four domains with distinct characteristics and functions 
[98,99]. The acidic domain and the adjacent glutamine (Gln)-rich domain make up the N-
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terminus half of PU.1. These domains are essential for PU.1’s capacity to transactivate 
genes [98,100]. The C-terminus consists of the DNA-binding domain which is 
homologous across the entire Ets family of proteins [98]. The PEST domain spans the 
middle of PU.1 and is necessary for interaction with other proteins like PU.1-interacting 
partner (Pip) in B cells [98,101]. The role of PU.1 in rendering B cell- or macrophage-
lineage commitment is dependent on the intracellular concentration of PU.1, where a high 
level of PU.1 is required for macrophage differentiation [102]. It was shown that PU.1 
drives progenitor cells toward the macrophage lineage by selectively binding to 
macrophage-specific enhancers [103]. Furthermore, studies discovered that PU.1 bound 
H3K4me1-marked genomic regions in macrophages, whereas the binding pattern of PU.1 
differed in B cells of various developmental stage [103,104]. PU.1-bound regions are also 
occupied by p300, fulfilling a criterion that is often used for identifying enhancers [103]. 
Thus, PU.1 shapes cellular identity of macrophages via selectively binding to enhancers 
that promote expression of macrophage-specific genes. However, gene expression 
profiles of macrophages are not dictated by PU.1 alone, but rather in concert with other 
TFs including CCAAT/enhancer binding protein (C/EBP) family of proteins and AP-1 
[104-106]. It has been shown that PU.1-bound enhancer regions also contained binding 
motifs for C/EBP and AP-1, resulting in co-localization of these TFs with PU.1 
[104,105]. Moreover, despite the importance of graded concentration of PU.1 in 
macrophage differentiation, the ratio of PU.1 to C/EBPα concentrations should also be 
taken into account, as high levels of C/EBPα can drive granulocyte and neutrophil 
development [107,108]. Therefore, macrophage differentiation is not determined solely 
by PU.1 but also its association and cooperation with other TFs. 
1.4.3 eRNAs 
Transcripts produced from active enhancers, eRNAs, are another considerable factor of 
gene regulation. eRNAs are a subclass of non-coding RNAs that are uni- or bi-
directionally transcribed by RNAPII and other components of the transcriptional 
initiation complex, which have been recruited to readily accessible enhancers [42]. 
Dissimilar to mRNA, majority of eRNAs do not acquire a poly(A) tail; hence, half-life of 
eRNAs tends to be shorter than that of mRNAs [42,73]. Regardless, rapid and dynamic 
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production of eRNAs by extracellular stimuli prompted investigators to examine the 
functional importance of eRNAs in gene regulation. Li et al. showed that knock-down of 
eRNAs with small interfering (si)RNAs and LNAs resulted in diminished levels of TFF1, 
FOXC1, and CA12 in 17β oestradiol-exposed MCF-7 cells [80]. Although the functional 
importance of eRNAs has been demonstrated, the mechanisms by which eRNAs regulate 
gene expression remain elusive. A potential mechanism of eRNA is its ability to promote 
RNAPII release from its pause phase by interacting with the NELF-DSIF complex [109]. 
NELF-DSIF complexes associate with nascent RNA through RNA recognition motif 
(RRM) in NELF, which accounts for the repressive function of the protein [109]. 
Schaukowitch et al. demonstrated that NELF is readily released from Arc and Gadd45b 
promoters in depolarized neurons; however, knock-down of eRNAs transcribed from 
enhancers located ~7 kilobases (kbs) upstream and downstream of Arc and Gadd45b, 
respectively, inhibited NELF dissociation from the promoters [109]. Subsequently, they 
also showed that NELF-E, a subunit of NELF that carries the RRM sequence, directly 
bound to Arc and Gadd45b eRNAs through pull-down assay [109]. This suggested that 
eRNAs compete with nascent RNA to interact with NELF via RRM, causing it to 
dissociate from RNAPII [109]. Moreover, another mechanism by which eRNAs affect 
the transcriptional output is through the recruitment of the Mediator complex at the 
promoter region of target genes [110,111]. It was shown that eRNAs physically interact 
with the Mediator complex subunit (MED) 1 and MED12 subunits of the Mediator 
complex, and siRNA-mediated knock-down of eRNAs directly reduced the co-
localization of the Mediator and RNAPII at the respective promoter region [110,111]. 
Furthermore, as enhancer-promoter interactions have been detected in many studies, the 
functional role of eRNAs in facilitating chromatin looping between enhancers and 
promoters was examined. Studies have shown that the frequency of spatial interactions 
between enhancers and promoters is significantly reduced upon depletion of eRNAs 
[80,110,111]. In line with eRNA-mediated formation of enhancer-promoter interactions, 
the Mediator complex behaves in a similar manner, as knock-down of MED1 and 
MED12 subunits inhibits chromatin looping between regulatory elements [110]. 
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1.4.4 Physical association of enhancers and promoters 
Enhancers are remotely positioned from their cognate genes. The distance between these 
genomic elements can extend as far as 2-3 Mbs. In order for enhancers to positively 
regulate gene expression, they must be in proximity with their target promoters 
[42,74,112]. Chromatin looping is a proposed model describing the interaction between 
distal regulatory elements and promoters in the nuclear space by extruding the 
intervening DNA [42,74]. In addition to eRNAs and the Mediator complex discussed 
above, major structural remodelers of the genome include CTCF and cohesin [113-116]. 
CTCF is an insulator protein that is largely deposited at borders of TADs [117]. Not only 
does this protein segregate active genetic segments from the inactive by sorting them into 
different compartments, it also has the ability to either activate or repress gene expression 
via enhancer blocking activities [117]. Notably, CTCF is a strong determinant of 
enhancer-promoter interactions along with cohesin, a protein complex structured like a 
ring [114,116,117]. Cohesin is primarily responsible for sister chromatid cohesion during 
DNA replication; however, it has been reported that cohesin associates with CTCF to 
remodel the chromatin landscape, and depletion of either protein attenuates the 
interaction frequency between enhancers and promoters [113,114,118,119]. In addition, 
cohesin is also known to co-localize with the Mediator complex [119]. Collectively, these 
findings infer that the interplay of various chromatin remodelers is crucial for the 
dynamic organization of the genome. 
1.4.5 Detection of enhancer-promoter interactions via Chromosome 
Conformation Capture (3C) analysis  
The most widely applied technology to analyze the genome architecture is 3C and its 
derivative high-throughput experiments such as 4C (circularized 3C-seq), 5C (3C-carbon 
copy) and Hi-C [120]. These techniques are favoured over other genome visualization 
techniques like light microscopy due to its sensitivity [121]. Additionally, another 
noteworthy advantage of 3C is that it can quantitate the interaction frequency of DNA 
segments in the nuclear space. Fig. 1.2 outlines the overall procedure of 3C analysis, 
which has been employed throughout this study to examine the intra-chromosomal 
interaction of the proposed enhancer and the IL-1β promoter. Initially, DNA regions in 
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proximity are crosslinked via formaldehyde fixation [120-123]. Following the isolation of 
the nuclei, fixed chromatins are exposed to restriction enzymes [120-123]. The choice of 
restriction enzyme should be carefully considered to obtain proper sizes of DNA 
fragments and avoid cleavage of the gene areas of interest [122]. Subsequently, ligation 
of digested DNAs is performed with preference of ligation between DNAs in close 
proximity [120-123]. Finally, the ligated products are de-crosslinked and purified to 
generate a collection of adjoined DNA segments commonly referred to as 3C library 
[122]. Quantification of 3C library is performed via real-time quantitative (q)PCR assays. 
Since a vast number of different combinations of ligated DNAs is generated in a given 
3C library, a specific ligation event can be very rare and occur 1/2000 to 1/20000 of the 
time [122]. Therefore, utilization of a sequence specific double-dye qPCR methods, such 
as TaqMan probes, rather than dye-based methods (SYBR Green), will increases the 
specificity of 3C analysis [122]. 
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Figure 1.2. Workflow of 3C analysis. The interacting DNA regions, particularly 
regulatory elements such as the promoter (orange box) and the enhancer (blue box) of a 
gene, are positioned in close proximity in the nuclear space via chromatin looping. The 
regulatory elements are crosslinked by formaldehyde (small red circles), followed by 
restriction enzyme digestion (black arrows) to cleave and remove any intervening DNA. 
The restriction enzyme-mediated cleavage of the DNA leaves either overhangs or blunt 
ends (represented as different coloured boxes at the ends of each DNA fragment), which 
are then re-ligated. Ligation of the crosslinked DNA regions generates target fragments in 
opposite orientations that can be amplified via qPCR. 
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1.5 Rationale, Hypothesis, and Research Aims 
Enhancers are genomic regulatory elements that determine the characteristics of each cell 
type. PU.1 is a LDTF that plays a key role in macrophage generation and differentiation 
by activating enhancers. Enhancers are often demarcated by unique histone 
modifications: H3K27Achi, H3K4me1hi, H3K4me3low. Based on these histone signatures 
available from the Encyclopedia of DNA Elements (ENCODE: 
https://genome.ucsc.edu/encode/) database, I identified a genomic region located ~10 kbs 
upstream of the IL-1β TSS as a potential enhancer (Fig. 3.1). I hypothesize that the 
genomic region is an enhancer that regulates the expression of IL-1β mRNA in a PU.1-
dependent manner in murine macrophages. Based on this hypothesis, I have proposed the 
following research aims:  
Aim I – Identifying the active enhancer of IL-1β in murine macrophages 
Aim II – Examining the role of PU.1 in the enhancer-promoter regulatory network of IL-
1β 
Aim III – Elucidating the role of PU.1 domains in the IL-1β regulatory network 
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Chapter 2 
2 Materials and Methods 
2.1 Reagents 
Dulbecco’s modified eagle medium (DMEM) and RPMI-1640 medium used to culture 
RAW264.7 macrophages and B16-BL6 melanoma cells, respectively, were purchased 
from Sigma Aldrich. Transfection reagents, Lipofectamine RNAiMAX and Polyjet, were 
obtained from Invitrogen and SignaGen Laboratories, respectively. PowerUPTM SYBR® 
Green Master Mix was from Applied Biosystems while dual-labeled Taqman probe (dye: 
JOE) and Hot Start Taq DNA polymerase were from Integrated DNA Technologies and 
New England Biolabs. Scrambled and eRNA-specific ASO were obtained from Exiqon. 
The primers used for qPCR assays were purchased from Eurofins genomics. QX200TM 
ddPCRTM EvaGreen supermix and droplet generation oil for EvaGreen were obtained 
from Bio Rad. The reagents utilized for 3C analysis include: Formaldehyde (VWR), 
DpnII, T4 DNA Ligase, and T4 DNA Ligase Buffer were from New England Biolabs, 
RNase (Qiagen), Proteinase K and Phenol:Chloroform:Isoamyl Alcohol (PCI) were 
purchased from Invitrogen. 
2.2 Cell culture and Transfection 
RAW264.7 macrophages were cultured in DMEM (high glucose) that contains 8% fetal 
bovine serum (Sigma – Aldrich), 10 mM MEM non-essential amino acids, 1 mM sodium 
pyruvate, 100 IU/mL penicillin, and 100 µg/mL streptomycin. B16-BL6 melanoma cells 
were cultured in RPMI-1640 medium that contains 10% fetal bovine serum (Sigma – 
Aldrich), 10 mM MEM non-essential amino acids, 1 mM sodium pyruvate, 100 IU/mL 
penicillin, and 100 µg/mL streptomycin. Throughout transfection of B16-BL6 cells with 
the transfection reagent, Polyjet, the cells were cultured in DMEM (high glucose, 10% 
FBS) containing all of the aforementioned components. All cells were cultured in an 
incubator with an optimal temperature of 37oC and CO2 level of 5%. 
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2.2.1 Transfection of RAW264.7 macrophages with ASO 
In order to transfect RAW264.7 macrophages with ASO (sequence in Table 2.1), 
Lipofectamine RNAiMAX was used according to the manufacturer’s instructions. Frozen 
(-80oC) RAW264.7 macrophages were thawed and cultured for two days prior to 
transfection. On the day of transfection, 7.0 x 105 cells were plated on 6-well plates and 
stabilized for three hours. Briefly, 250 pmole of scrambled and eRNA-specific ASO were 
mixed with Opti-MEM (reduced serum medium – Gibco). Simultaneously, 
Lipofectamine RNAiMAX was mixed with Opti-MEM in a different vial. The two 
components were mixed and incubated for 15 mins. ASO-Lipofectamine complexes were 
then thoroughly deposited into respective wells, and the cells were transfected for 22 
hours. Upon completion of transfection, the cells were divided into non-LPS vs LPS 
groups, and re-seeded on 6-well plates. The cells were then stimulated with LPS (100 
ng/mL) for 90 mins. 
2.2.2 Transfection of B16-BL6 cells 
2.2.2.1 Reprogramming of melanoma cells with LDTFs 
B16-BL6 cells cultured for two days before being transfected. Reprogramming of B16-
BL6 cells initially requires transfection of the cells with LDTFs. Polyjet was employed to 
transfect B16-BL6 cells according to the manufacturer’s instructions. 5.0 x 105 B16-BL6 
melanoma cells were re-plated on 6-well plates and cultured in RPMI-1640 medium one 
day prior to transfection. On the following day, the RPMI medium was replaced with 
high glucose DMEM. 0.7 µg of control pcDNA3, pcDNA3-PU.1 and/or pBR322-
C/EBPα plasmids, which were generously donated by Dr. Dekoter’s lab (UWO), were 
thoroughly mixed with the Polyjet media (serum-free DMEM). In another vial containing 
Polyjet media, Polyjet was added and carefully mixed. The plasmid and Polyjet 
containing solutions were carefully mixed and incubated for 15 mins to form plasmid-
Polyjet complexes. The complexes were then added into each well and incubated for 24 
hours. After five hours of transfection, extra media was added into each well to lower 
cytotoxicity. For eRNA and IL-1β mRNA analysis, the transfected cells were divided into 
non-LPS vs LPS groups, re-plated on 6-well plates, and incubated in RPMI-1640 medium 
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for another 24 hours. The LPS group was then stimulated with 100 ng/mL of LPS for 6 
hours.  
2.2.2.2 Introduction of ASO 
For the eRNA knock-down study, the melanoma cells initially transfected with LDTFs 
(post 24 hours) were divided into scrambled vs eRNA-specific ASO groups and re-plated 
on 6-well plates. On the next day (48 hours post transfection), identical protocol for 
transfection with LDTFs was performed to transfect the cells with 250 pmole of either 
scrambled or eRNA-specific ASO for 22 hours. Once the transfection was done, the 
melanoma cells were exposed to LPS (100 ng/mL) for 6 hours.  
2.3 RT-qPCR  
The cells were harvested upon completion of LPS stimulation for the indicated time 
points. 250 µL of TRIzol was used to extract the total cellular RNA from the harvested 
cells. cDNA was prepared in 20 µL reaction mixtures containing 1 µg of the isolated 
RNA, dNTPs, poly-N6 (random) primers, and Moloney murine leukemia virus reverse 
transcriptase. The following conditions were used for synthesis of cDNA: 65oC for 5 
mins (predenaturation),25oC for 10 mins (extension), 42oC for 1 hour (cDNA synthesis), 
90oC (termination). Subsequently, qPCR assays were performed with 10 µL qPCR 
reaction mixtures that consisted of 1 µL of cDNA, PowerUPTM SYBR® Green Master 
Mix (1X), forward and reverse primers (500 nM), and distilled water. The following 
conditions were used for qPCR analyses: 50oC for 2 mins, 95oC for 2 mins, 40 cycles of 
95oC for 15 secs/ 58 - 60oC for 30 secs/72oC for 20 secs/83oC for 15 secs. The Rotor-
Gene 6 software was used to generate Ct values and analyze melting curves. Expression 
levels of IL-1β mRNA and eRNAs were normalized to the housekeeping gene, GAPDH, 
and quantified via ∆∆Ct analysis. The sequences of GAPDH mRNA, IL-1β mRNA, and 
eRNAs are listed in Table 2.1. The amplicon size of the qPCR products was examined by 
gel electrophoresis. 
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2.4 Droplet Digital PCR  
cDNA synthesized via RT-PCR was used to measure the absolute quantities of eRNAs. 
Reaction mixtures and oil droplets were generated with QX200TM ddPCRTM EvaGreen 
supermix and droplet generation oil for EvaGreen, respectively, according to 
manufacturer’s instructions. Initially, 25 µL reaction mixtures comprised of 1.25 µL of 
cDNA, the EvaGreen supermix (1X), eRNA primer sets (100 nM), and water for 
molecular biology (EMD Millipore) were prepared. The prepared reaction mixture and 
the droplet generation oil were transferred into the respective wells of a DG8 cartridge. 
The cartridge was loaded in the QX200 droplet generator, and the generated oil droplets 
(number varies between 15,000 – 20,000 droplets) were then transferred onto a ddPCR 
96-well plate, which was enclosed with heat-sealing aluminum foil. PCR was 
subsequently carried out. The following conditions were used for PCR: 95oC for 5 mins 
(enzyme activation), 40 cycles of 95oC for 30 secs (denaturation)/ 58oC for 1 min 
(annealing/extension), 4oC for 5 mins/90oC for 5 mins (signal stabilization). Once PCR 
was finished, the 96-well plate was then loaded in the QX200 droplet reader. QuantaLife 
was used to analyze fluorescence measurements.  
2.5 Culturing and isolating subpopulations of CRISPR cells  
B16-BL6 melanoma cells were cultured for two days prior to transfection with CRISPR 
editing plasmids. Polyjet was the transfection reagent used, and the same protocol as 
described in section 2.2.2.1 was employed. The total amounts of CRISPR editing 
plasmids used were 1.0 µg and 1.5 µg. Each group of cells were pulled and genotyped. 
The remainder of the cells were frozen (-80oC). The absence or presence of the enhancer 
was analyzed via gel electrophoresis. The sequences of the validation primers are listed in 
Table 2.1. Then, the frozen cells (1.0 µg group) were re-cultured, and a total of 100 cells 
were re-seeded on a 10 cm plate. Re-plated cells were cultured for nearly two weeks 
while checking for the growth of each subpopulation daily. Once the aggregates of cells 
could be seen with the naked eye, the 10 cm plate was thoroughly washed with fresh 
PBS, and 2 µL of trypsin was used to detach and pick out each subpopulation of cells. 
The cells were transferred onto a 24-well plate, and re-grown for another week. Once 
each well reached confluency of 70-80%, the cells were harvested, genotyped, and 
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analyzed for enhancer knock-out by gel electrophoresis. Single cell colonies of a 
subpopulation of interest was re-analyzed using the same protocol as described above. 
2.6 Chromosome Conformation Capture (3C) 
The general outline of sample preparation for 3C analysis is depicted in Fig. 1.1. Initially, 
a total of 1.2 x 107 cells of wild-type and LPS-stimulated RAW264.7 macrophages, and 
wild-type, pcDNA3-PU.1 and/or pBR322-C/EBPα-overexpressed B16-BL6 melanoma 
cells were prepared. 1.0 x 107 cells were then harvested, thoroughly washed with PBS 
two times, and resuspended in 12 mL of PBS (room temperature). Formaldehyde (2%) 
was added to crosslink the DNA for 10 mins at room temperature while tumbling. The 
tubes were immediately put on ice after formaldehyde fixation and 1 M glycine (0.125 
M) was added to terminate crosslinking. The samples were spun at 805 x g for 8 mins at 
4oC. The collected pellet was washed with PBS. The samples were re-spun at 805 x g for 
8 mins at 4oC. PBS was removed and the cell pellet was resuspended in 3 mL of pre-
made lysis buffer (ice cold). The cells were lysed for 15 mins at 4oC. The lysis buffer 
contained the following components: NaCl (10 mM), Tris-HCL (10 mM; pH 8.0), NP-40 
(0.2%), distilled water, and cOmpleteTM, EDTA-free protease inhibitor cocktail tablet 
(1X). Once finished, the lysed cells were spun down at 805 x g for 8 mins at 4oC. The 
pellet of extracted nuclei was washed with PBS, and transferred to a new Eppendorf tube. 
The resuspended nuclei were spun down at maximum speed for 1 min at 4oC. The 
supernatant was carefully removed, and the extracted nuclei was snap-frozen in liquid N2 
and stored in -80oC. Simultaneously, 2.0 x 106 cells were also harvested and resuspended 
in TRIzol. In order to ensure that the prepared cells generated expected responses, IL-1β 
mRNA and eRNA expression levels were analyzed in these samples prior to 
digestion/ligation steps of the extracted nuclei. 
Frozen nuclei were thawed and resuspended in 500 µL of 1.2x restriction enzyme (DpnII) 
buffer. 20% SDS was added (final: 0.3%), and incubated at 37oC for 1 hour shaking at 
1000 rpm. 20% Triton X-100 (final: 2.0%) was then added, and incubated again at 37oC 
for 1 hour shaking at 1000 rpm. 10 µL of the undigested DNA was aliquoted and stored (-
20oC), which was used to determine the digestion efficiency. 400 U of DpnII was added 
to the remainder of undigested DNA, and incubated at 37oC for 24 hours shaking at 1000 
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rpm. Afterwards, 10 µL of the digested DNA was also aliquoted and stored in -20oC. Post 
digestion of the DNA, 20% SDS (final: 1.6%) was added to the tube. The mixture was 
incubated at 65oC for 25 mins while shaking at 1000 rpm. The digested DNA was 
transferred into 50 mL falcon tubes, and 6.125 mL of the prepared ligase buffer (1.15x) 
and 20% Triton X-100 (final: 1.0%) were also added. The samples were incubated at 
37oC for 1 hour while tumbling. Following incubation, 800 U of T4 DNA ligase was 
added and incubated at 16oC for 72 hours. Once done, the tubes were allowed to reach 
room temperature, and 160 µL of 0.5 M EDTA was added to inhibit the ligase activity. 
The ligated DNA was de-crosslinked with proteinase K (500 µg) at 65oC overnight. On 
the following day, another 500 µg of proteinase K was added and incubated for another 2 
hours. DNA was extracted with 7 mL of PCI twice and subsequently with 7 mL of 
chloroform once. The tubes were centrifuged for 10 mins at room temperature at 2465 x 
g. 7 mL of distilled water, 1 mL of 3M sodium acetate, and 19.25 mL of 100% EtOH 
were added to the retrieved aqueous phase (7 mL), and stored at -20oC overnight. The 
samples were spun at 2465 x g for 1 hour at 4oC. The pelleted DNA was washed with 
70% EtOH, then briefly air-dried. 400 µL of 10 mM Tris-HCl (pH 8.0) was used to 
resuspend the pellet. RNase (300 µg) was added and incubated at 37oC for 45 mins. DNA 
was extracted again with 400 µL of PCI and chloroform (once each). The samples were 
centrifuged at max speed for 5 mins at room temperature. Same ratio of each component 
was added to the retrieved aqueous phase, and stored at -20oC for 2 hours. DNA was 
pelleted by centrifuging at max speed for 30 mins at 4oC, washed with 70% EtOH, and 
re-spun at same speed for 5 mins. 3C library was finally prepared by resuspending the 
air-dried pellet in 200 µL of distilled water. Taqman qPCR was employed to analyze 
enhancer-promoter interactions in the samples. The sequences of the primers and dual-
labeled Taqman probe are shown in Table 2.1. The following conditions were utilized for 
Taqman qPCR: 95oC for 15 mins, 46 cycles of 95oC for 10 secs/55-58oC for 20 secs/65oC 
for 40 secs. 
2.6.1 Restriction Enzyme Digestion 
Restriction enzyme digestion efficiency is a critical step in 3C sample preparation. In 
order to determine the digestion efficiency, extracted nuclei were digested with 100 U, 
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200 U, 400 U, and 600 U of DpnII. Moreover, the effect of freeze and thawing the nuclei 
was examined by either freeze and thawing the sample digested with 600 U of DpnII or 
immediately processing it. Instead of taking 10 µL aliquots of undigested and digested 
DNA, the samples were divided in half. Other than the fact that the ligation step was 
omitted, identical protocol as described above was used to prepare 3C library of 
undigested and digested DNA. SYBR Green-mediated detection of fluorescence was 
performed in this experiment with the same qPCR conditions used in section 2.3. The 
primer sets, shown in Fig. 2.1 (sequences are listed in Table 2.1), used to determine the 
digestion efficiency were designed to target either within a DNA fragment from the IL-1β 
promoter or the adjacent DpnII-mediated cleavage site.  
2.7 Statistical Analysis  
Data were analyzed with statistical tests indicated in the figure legends. GraphPad Prism 
6.0 was used to perform statistical analysis. Data are expressed as means ± S.D. (n=3). 
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Table 2.1. List of sequences of ASO, qPCR primers, CRISPR validation primers, 3C 
analysis primers, and restriction enzyme digestion efficiency primer. 
Experiment Target Primer Sequence 
ASO 
Scrambled AACACGTCTATACGC 
eRNA CAATCCTGGTTGATGA 
qPCR/ddPCR 
GAPDH F: GCATTGTGGAAGGGCTCATG 
R: TTGCTGTTGAAGTCGCAGGAG 
IL-1β F: GTGGACCTTCCAGGATGAGG 
R: GCTTGGGATCCACACTCTCC 
534 eRNA F: CCTGACCCACACAAGGAAGT 
R: ATGTGCGGAACAAAGGTAGG 
1251 eRNA F: TACTGCCTGCATCCATCTGC 
R: GGGAGCTCTTCTTGCTTGGA 
2258 eRNA F: ATGTTGTGCAACTTGCCTGC 
R: AGGAGGTTTGTCTGGGAGGA 
2860 eRNA F: ATGAGAGGGAAAGAACAGACCC 
R: GCTAAGCAATGACTGTCCTCA 
3236 eRNA F: ACTTGGGGAGGAAAGGATGT 
R: ATGAGGAGCAAGCCAGTGAG 
4152 eRNA F: AGTGCATGTTCCAACGTCAA 
R: GACCATCAAGAACAGCAGCA 
5370 eRNA F: CTAGTCCCAGGGAGTTCTGC 
R: AGGGTTAGGCGCTATGGTCT 
6212 eRNA F: CTATGGCCTATGGCTTCTGC 
R: TTTTGCCACATGGCTGATAA 
7182 eRNA F: ACAGTCTCGCCACAGAAAGAA 
R: CCATCAAAAGGACAACTGCAT 
7951 eRNA F: AATCACGAACAGACGACCATC 
R: GCCTCCCTATCTCCCTACCTT 
8453 eRNA F: AGTAGTACCAGAGCCCCATGT 
R: GCTTCCCTTTGCATCTAGCA 
9013 eRNA F: GGGTTTAAGGGTCTGGTCTTG 
R: CAGAAAGCTGGGAATTGGAG 
9236 eRNA F: CATCAACCAGGATTGGACGTG 
R: GCACTGGGGATCCTATTAACC 
9486 eRNA F: CGGGGAAGTGGCTGATAGTA 
R: TCAGGCTTCCTTCAGTGGAT 
10368 eRNA F: ATGGAGCCCATCCCAGAG 
R: AGTTACCAGCAGGGCCACTC 
10841 eRNA F: AGCCGGAGCTAAAATGGAGAC 
R: CCACCACCCCAAGGACTTATC 
11743 eRNA F: AGACATTGCCCTCCAGATCC 
R: CTGGGGAAAAGATGGGCAAC 
13252 eRNA F: CGCTTATGTTGGGAATTTGG 
R: TCACAGAAGCAGGCAAGATG 
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14256 eRNA F: CCCAGGAAAGTGACGTTGTT 
R: GACCTTGCTTCCACTCTTGC 
15232 eRNA F: GGCCCAGGGAGTAGCTCTAT 
R: TGGAGGGGCTGAGAGTTCTA 
CRISPR 
Validation 
12001 CRISPR F CCCCACCAGTTATGCTATACG 
11780 CRISPR R CCAACAATTCAGCAAGAGCA 
5794 CRISPR R ACTTCATCTCCAGTTAGCCTGC 
3C 
Dual-labeled 
Taqman probe 
5’-JOE/TCGTTCACCACC/ZEN/ 
TTTGCACTGTGCAAC/BkFQ-3’ 
Universal Forward TGCTCATGAACAGGCAGATG 
Reverse #1 TTGTCTGGGAGGATTTGGAG 
Reverse #2 TCTGTAGGCAAGCCTGT 
Reverse #3 GATGCAAGTACCATGGGATG 
Reverse #4 AAAGGAAAGTGGTGTGTTTGTG 
Reverse #5 GCTGGTGGTTCTGGGTTCTA 
Reverse #6 AGGGCAACTTTGTGCAGATG 
Reverse #7 CCATCTCCTCACTCCCTTCC 
Reverse #8 GCCATCAAAAGGACAACTGC 
Reverse #9 CGACCATCAATGAGACCAAA 
Reverse #10 CTCTCCAGCACCCGTGAAT 
Reverse #11 AGACCAGACCCTTAAACCCT 
Reverse #12 TTCCGATTCACTTCCTCACC 
Reverse #13 TGCGTTGTAGTTGAAGCTGT 
Reverse #14 CTAACCCCTTCCAACACCT 
Reverse #15 GCTTACTCTGACTGCTTGCC 
Reverse #16 GTGTTCTCAGGCTGCCTTTC 
Restriction 
Enzyme 
Digestion 
Efficiency 
Undigested DNA F: CCTGACCCACACAAGGAAGT 
R: ATGTGCGGAACAAAGGTAGG 
 
Digested DNA F: TGCTCATGAACAGGCAGATG 
R: TATCCCTTTTCCAGGTCTCC 
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Figure 2.1. Visual representation of primer design for restriction enzyme digestion 
efficiency. The image displays two adjacent DNA fragments, which have been generated 
by DpnII-mediated digestion (red dotted lines), within the promoter of IL-1β. Two sets of 
primers have been designed to determine the digestion efficiency of the DNA in 3C 
samples. The digested (DIG F&R) primer set targets the DNA region that contains DpnII 
cleavage site (5’-GATC-3’), whereas the undigested (UND F&R) primer set amplifies a 
genomic region within a fragment. The PCR products produced by the DIG primers were 
compared to the amplicons produced by the undigested primers, which represent 
maximum amplification and were used as the control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
UND F
UND R
DIG F
DIG R
IL-1β TSS
5’
5’
3’
3’
IL-1β TSS
32 
 
Chapter 3 
3 Results 
3.1 Identifying the active enhancer of IL-1β in murine 
macrophages 
3.1.1 The genomic region with enhancer histone modifications is 
macrophage-specific 
As a means to identify a potential active enhancer of IL-1β, I sought for a genomic region 
with enhancer-associated histone markers (H3K27Achi, H3K4me1hi, H3K4me3low) in a 
100 kilobase (kbs) frame of window (± 50 kbs from IL-1β TSS). Based on the chromatin 
immunoprecipitation sequencing (ChIP-seq) analysis of the chromatin markers available 
in the ENCODE database as illustrated in Fig. 3.1A, I located a potential active enhancer 
enriched in H3K27Ac, H3K4me1, and devoid of H3K4me3 approximately 10 kbs 
upstream of the IL-1β TSS in murine bone marrow-derived macrophages (BMDMs). 
Considering that enhancers are cell-type specific regulatory elements, histone 
modification profiles of other cell lines including B-cell lymphomas (CH12), liver, and 
brain cells were also analyzed. The non-myeloid cell lines lacked the unique histone 
markers at the potential enhancer region, suggesting that the genomic region serves as a 
macrophage-specific enhancer of IL-1β. Furthermore, two binding motifs of PU.1 (5’-
GAGGAAGT-3’; core motif highlighted in red in Fig. 3.1B), which activates 
macrophage-specific enhancers in combination with other LDTFs, are located within the 
putative enhancer, indicating that PU.1 potentially recognizes and binds to this regulatory 
element in BMDMs. 
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Figure 3.1. A putative enhancer marked by H3K27Ac/H3K4me1/H3K4me3 within a 
100 kbs window of IL1β locus in murine BMDMs. A) The ChIP-seq data from the 
ENCODE database shows a putative enhancer region, which recruits high levels of 
H3K27Ac and H3K4me1 and low levels of H3K4me3 in BMDMs, but not in CH12, 
liver, and brain cells. B) A zoomed in image of the highlighted region shown in (A). The 
highlighted region represents the position of the proposed enhancer (H3K27Achi, 
H3K4me1hi, H3K4me3lo, RNAPIIhi) relative to the IL-1β TSS. The two arrows within the 
putative enhancer indicate the location of PU.1 binding motif (5’-GAGGAAGT-3’). 
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3.1.2 The putative genomic element produces eRNAs in response to LPS 
in murine macrophages 
Active enhancers recruit RNAPII, along with other transcription factors and produce 
eRNAs [42,73]. As a means to examine whether eRNAs are generated from the proposed 
enhancer of IL-1β, 12 qPCR primer sets that target approximately every 500-1000 bps in 
genomic regions upstream, downstream, and within the putative enhancer were designed 
to quantitatively measure the production of non-coding transcripts in LPS-activated 
macrophages (Fig. 3.2A). Black horizontal bars show the positions of these eRNA 
primers relative to the IL-1β TSS. It was observed that the expression levels of eRNAs 
were dependent on the duration of macrophage exposure to LPS (Fig. 3.2B). Using 2 
representative primer sets (9013, 11743), which produced greatest eRNA fold increase in 
Fig. 3.2B, to further analyze eRNA production, I found that eRNAs were rapidly induced 
and peaked at 90 mins post-stimulation of the macrophages, which then gradually 
decreased to a basal level after 720 mins (Fig. 3.2C). Then, the kinetics of IL-1β mRNA 
production in the same set of samples were examined to address whether the IL-1β 
mRNA was generated in a time-dependent manner upon LPS exposure (Fig. 3.2D). I 
observed a correlation between the eRNAs and IL-1β mRNA productions. The kinetics of 
IL-1β mRNA production was slightly delayed in comparison to the eRNAs and reached 
maximal production 180 mins after LPS stimulation. 
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Figure 3.2. The production of eRNAs and IL-1β mRNA by LPS in macrophages. A) 
A schematic presentation of H3K27Ac ChIP-seq peaks in BMDMs based on the the 
ENCODE database and eRNA primer sets. The black horizontal bars and numerical 
values indicate the location of eRNA primers and the number of base pairs upstream of 
the IL-1β TSS (red arrow). B - D) RAW264.7 cells were stimulated with LPS (100 
ng/mL) for the time indicated. Expression of eRNAs (B, C) and IL-1β mRNA (D) were 
analyzed by RT-qPCR using GAPDH as the housekeeping gene. Fold inductions of 
eRNAs and IL-1β mRNA were compared between untreated and LPS-stimulated (each 
time point) RAW264.7 macrophages. The data are expressed as means ± S.D. (n=3); *, P 
< 0.05, **, P < 0.05, ***, P < 0.05, Student’s t test. 
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3.1.3 Measurement of LPS-induced eRNA production by droplet digital 
(dd)PCR 
A notable limitation of real-time PCR approach is that it only measures a relative quantity 
(fold change) of template in a given primer set, and absolute quantities of template cannot 
be obtained. Taking this into consideration, I used the ddPCR to measure the absolute 
quantity of eRNAs (template), which allows comparison between different primer sets 
[124,125]. ddPCR utilizes the power of oil droplets by partitioning a sample of DNA into 
thousands of droplets. Each droplet contains all the necessary components to run a PCR 
assay [126]. Thus, as opposed to detecting the fluorescence signal of a single reaction in a 
standard qPCR, thousands of reactions are simultaneously carried out in a typical ddPCR 
[126]. Depending on whether a copy of the target DNA is allocated in the oil droplets or 
not, either a positive or a negative signal is generated, respectively [126]. Based on the 
ddPCR fluorescence data in Fig 3.3A, it is apparent that there was an increase in the 
number of positive droplets in LPS-stimulated macrophages. However, one factor that 
must be taken into consideration when analyzing a ddPCR fluorescence data is that the 
total number of oil droplets generated varies between samples. In order to overcome this 
issue, the concentrations of positive droplets (unit: fluorescent droplets/µL), which were 
generated via QuantaLife software, were used as the unit of measurement to make direct 
comparisons between untreated and LPS-treated RAW264.7 cells (Fig. 3.3B). 
Expectedly, elevated concentrations of eRNAs were observed in macrophages 60 mins 
post LPS exposure. Specifically, concentrations of eRNAs detected by 8453, 9013, 9236, 
9486, 10368, and 10841 primer sets were induced up to ~20-folds in LPS-stimulated 
macrophages, whereas the amount of transcripts produced from the other regions 
remained similar to the basal level.  
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Figure 3.3. Measurement of copy numbers of eRNAs by ddPCR in macrophages 
activated by LPS. A) Illustration of ddPCR fluorescence graphs for eRNA production 
between wild-type and LPS-stimulated (60 mins) RAW264.7 macrophages. The blue dots 
that are positioned above the threshold line (pink) represent positive droplets whereas 
negative droplets are depicted as black dots. The standard RT-PCR was used to generate 
cDNA from the eRNAs produced in the cells. The fluorescence of each oil droplet has 
been detected via EvaGreen dye. B) Concentration of eRNAs in copies/µL (solid line) 
from each sample was derived from the number of positive droplets shown in (A). The 
concentration of eRNAs in LPS-stimulated macrophages was compared to the 
background eRNA concentration from wild-type macrophages, and was represented as 
fold changes. The dotted line represents the fold changes of eRNAs in LPS60 RAW264.7 
macrophages quantified via qPCR. 
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3.1.4 Examining the role of the putative eRNA in IL-1β mRNA 
production 
To address the role of the putative eRNA in promoting IL-1β transcription, a loss-of-
function experiment was performed using the antisense locked nucleic acid (LNA™) 
GapmeR (herein termed ASO). Except for a few nucleotides along the middle stretch of 
the single-stranded ASO, 5’ and 3’ ends comprise LNAs, which are modified nucleotides 
with an oxymethylene bridge connecting the 2’ oxygen and 4’ carbon [127]. Such 
structural modifications increase the overall rigidity of the ASO [127]. Furthermore, the 
DNA(ASO):RNA heteroduplex are cleaved by RNase-H that are abundant in the nucleus 
[127]. Considering that eRNAs are localized in the nucleus, ASO forms a stable duplex 
with target RNAs and leads to the degradation of RNAs by RNase-H [127]. Transfection 
of RAW264.7 cells with the ASO targeting the putative anti-sense eRNA (eRNA-ASO; 
targeting 9237-9253 bps upstream of the IL-1β TSS) suppressed 64%, 52%, and 78% of 
amplicons produced from 10841, 10368, and 9486 primer sets, respectively, whereas 
random ASO (scrambled-ASO) had no effect (Fig. 3.4A). Also, cells transfected with 
eRNA-ASO decreased the production of IL-1β mRNA by ~50% compared to cells 
transfected with scrambled-ASO (Fig. 3.4B). These results indicate that the putative 
eRNA is required for optimal production of IL-1β mRNA. 
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Figure 3.4. Knock-down of the putative eRNA reduces IL-1β mRNA production in 
RAW264.7 macrophages. A and B) RAW264.7 macrophages were transfected with 250 
pmole of scrambled-ASO or eRNA-ASO for 24 hours. These cells were then stimulated 
with LPS (100 ng/mL) for 90 mins. Productions of the putative eRNA (A) and IL-1β 
mRNA (B) were measured using RT-qPCR using GAPDH as the reference gene. The 
data are expressed as means ± S.D. (n=3); *, P < 0.05, ***, P < 0.05, ****, P < 0.05, 
Student’s t test. 
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3.1.5 LPS enhances the physical interaction between the putative 
enhancer and IL-1β promoter in macrophages 
Enhancers are often distally positioned from the promoter region and these regulatory 
elements should be brought in close proximity via chromatin looping (i.e. looping out the 
intervening DNA) [128-131]. The physical interaction between these regulatory elements 
has been suggested to be mediated by the interplay of eRNAs and various transcription 
factors such as RNAPII and the Mediator complex [132]. Thus, I utilized the 3C 
technique to examine the interaction between the putative enhancer and IL-1β promoter 
in LPS-exposed RAW264.7 macrophages. Initially, the digestion efficiency of the 
restriction enzyme of choice had to be determined prior to 3C sample preparation. It has 
been suggested that the digestion efficiency of the chromatin should at least be 60-70%, 
as low digestion efficiency can generate inaccurate quantification results [122]. I decided 
to use the restriction enzyme DpnII, which recognizes 5’-GATC-3’ and cleaves before G, 
that renders ~500 bp size genomic DNA fragments. First, I optimized the digestion 
condition by testing varying amounts of DpnII to yield ≥ 70% digestion efficiency (Fig. 
3.5) [133,134]. I found that the minimum amount of DpnII required to reach ~70% 
digestion efficiency was 400 U. Next, I found that the crosslinked DNA should go 
through a round of freeze (-80oC) and thaw cycle prior to digestion to increase the 
digestion efficiency by ~25%. 
Through 3C-TaqMan qPCR analysis, I found that the interaction between the IL-1β 
promoter and proximal fragments occurred in both non-treated and LPS-treated (180 
min) macrophages (Fig. 3.6 B, C). As the DNA is not in linear form and is densely 
packaged in the nucleus, the promoter and the proximal fragments are likely situated in 
proximity in the nuclear space. Since 3C measures the ligation frequencies between 
fragments based on their proximity, the ligation between the promoter and the proximal 
fragments in untreated and LPS-stimulated RAW264.7 cells likely occurred by chance 
and was considered as background interaction. However, we observed that the ligation 
between the promoter of IL-1β with both 3’- and 5’-ends of the putative enhancer 
occurred upon stimulation of macrophages with LPS for 180 mins (Fig. 3.6C), which was 
absent in wild-type cells (Fig. 3.6B). The grey upright bars represent the frequency of 
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interaction between the IL-1β promoter and the crosslinked genomic fragment. It is 
important to note that Fig. 3.6C only displays new enhancer-promoter interactions 
detected upon LPS challenge. Overall, these results are a clear indication that enhancer-
promoter interactions are stimulus-dependent in murine macrophages.  
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Figure 3.5. Optimization of restriction enzyme digestion for 3C analysis. RAW264.7 
cells (1.0 x 107) were fixed with formaldehyde for crosslinking of interacting DNA 
regions and then the genomic DNAs were extracted. Extracted DNAs were digested with 
varying amounts of DpnII (100, 200, 400, 600 U), and the DNAs digested with 600 U of 
DpnII underwent a round of freezing and thawing (FT; NFT: No FT). Digested DNA 
fragments were de-crosslinked with proteinase K and subsequently extracted. Digestion 
efficiency was measured via qPCR with primer sets targeting undigested and digested 
genomic regions.  
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Figure 3.6. LPS stimulation induces enhancer-promoter interaction in macrophages. 
A) Dotted lines represent possible cleavage sites by DpnII (400 U), and arrows indicate 
the primers used to probe the digested DNA fragments. Each reverse primer (black) was 
utilized in combination with the promoter-recognizing universal forward primer (red). B 
and C) RAW264.7 cells were treated with none (A) or LPS for 180 mins (B) and fixed by 
formaldehyde. DNAs were then digested with DpnII (400 U) and ligated for 72 hours. 
The physical interaction between the regulatory elements were quantified via TaqMan 
qPCR. The arrows extending from the IL-1β promoter to the DNA fragments generated 
by DpnII indicate the occurrence of ligation. The upright bars represent the ligation 
frequencies between the promoter and interacting DNA fragments, which have been 
compared to the ligation frequency of two adjacent DNA fragments in the promoter 
region. 
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3.2 Examining the role of PU.1 in the enhancer-promoter 
regulatory network of IL-1β 
3.2.1 Overexpression of PU.1 is sufficient for inducing IL-1β mRNA 
expression in B16-BL6 murine melanoma cells 
Rapid production of IL-1β in response to microbial infection is a feature of innate 
immune cells, such as macrophages, and this unique phenotype is likely due to regulatory 
elements that allow prompt transcriptional initiation triggered by extracellular signals. As 
shown in Fig. 3.1, the macrophages harbor an active enhancer (H3K27Achi, H3K4me1hi, 
H3K4me3low), which is not detected in other cell lines. Since LDTFs play key roles in 
determining cell identities, I have examined the role of LDTFs involved in macrophage 
differentiation including PU.1 and C/EBPα in regulating the putative enhancer for IL-1β. 
As shown in Fig. 3.7A, transfection efficiency of B16-BL6 melanoma cells is very high, 
as mRNA expression levels of PU.1 and C/EBPα increased by ~40000- and ~500000-
fold, respectively, compared to vector control (VC) transfected cells. Furthermore, B16-
BL6 cells are able to activate the mitogen-activated protein kinases (MAPKs: 
extracellular regulated kinases (ERKS) and p38 MAPK) within 60 mins in response to 
LPS (Appendix A). Therefore, these cells could be an ideal system to examine the role of 
LDTFs in regulating IL-1β production. As shown in Fig. 3.7B, ectopic expression of 
PU.1 rendered these cells to express IL-1β mRNA in response to LPS. In contrast, 
C/EBPα overexpression did not induce the production of IL-1β mRNA. Concomitant 
expression of PU.1 and C/EBPα did not change IL-1β mRNA expression levels when 
compared to cells overexpressed with PU.1 alone. These results suggest that PU.1 alone 
is sufficient for rendering B16-BL6 melanoma cells to produce IL-1β in response to LPS.  
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Figure 3.7. The production of IL-1β mRNA in response to LPS is dependent on the 
overexpression of PU.1 in B16-BL6 melanoma cells. A) B16-BL6 cells were 
transfected with VC or PU.1 and/or C/EBPα (0.7 µg each) plasmids for 48 hours. The 
expression levels of PU.1 and C/EBPα were analyzed via qPCR, and normalized to 
GAPDH. Data are expressed as means ± S.D. (n=3); *, P < 0.05, **, P < 0.05, Student’s t 
test. B) B16-BL6 cells were ectopically expressed with the same plasmids as described in 
(A) and stimulated with LPS (100 ng/mL) for 6 hours. IL-1β mRNA production was 
quantified via qPCR. Data are expressed as means ± S.D. (n=3); ***, P < 0.05, Student’s 
t test.  
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3.2.2 Overexpression of PU.1 induces the activation of the putative IL-
1β enhancer 
Since overexpression of PU.1 rendered B16-BL6 cells to induce IL-1β mRNA expression 
(Fig. 3.7B), I have examined whether PU.1 overexpression also activated the putative 
enhancer found in macrophages (Fig. 3.1). As shown in Fig. 3.8A, overexpression of 
B16-BL6 cells with either PU.1 alone or PU.1 and C/EBPα induced basal level of eRNA 
transcription prior to LPS stimulation, whereas C/EBPα had a minimal effect. 
Subsequently, I investigated the effect of LPS stimulation on eRNA production in cells 
ectopically expressing either PU.1, C/EBPα or both PU.1 and C/EBPα. Fig. 3.8B displays 
that LPS increased the production of transcripts by approximately 3-fold from regions 
targeted by 14236, 13252, 9486, and 8453 primer sets. The greatest fold increase (~10-
fold) in eRNA was detected by the 10841 primer set. Similar to IL-1β mRNA data, 
C/EBPα did not have much contribution in promoting transcription of eRNAs in response 
to LPS (Fig. 3.8C). Moreover, combination of PU.1 and C/EBPα generally increased the 
production of eRNAs upon LPS stimulation (Fig. 3.8D); however, most of these fold 
increases turned out to be statistically insignificant. Interestingly, LPS-induced eRNAs 
detected by 11743 and 10841 primer sets in PU.1- and C/EBPα-overexpressed cells 
elevated by ~4-fold. 
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Figure 3.8. eRNAs are readily produced in PU.1-overexpressed B16-BL6 melanoma 
cells in response to LPS. A-D) B16-BL6 cells were overexpressed with PU.1 and/or 
C/EBPα (0.7 µg each) for 48 hours, then either unstimulated or stimulated with LPS (100 
ng/mL) for 6 hours. The production of eRNAs in cells transfected with VC, PU.1, 
C/EBPα, or both LDTFs was measured via qPCR prior to LPS stimulation (A). Fold 
changes in eRNA production were compared between unstimulated or LPS stimulated 
B16-BL6 cells overexpressed with PU.1 (B), C/EBPα (C), or both LDTFs (D). 
Production of eRNAs was quantified by qPCR. GAPDH was the housekeeping gene used 
to analyze eRNA expression. Data are expressed as means ± S.D. (n=3); **, P < 0.05, 
***, P < 0.05, ****, P < 0.05, Student’s t test. 
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3.2.3 Examining the role of the putative IL-1β regulatory element by 
gene editing 
To address the role of the putative enhancer identified through the ENCODE database, 
the regulatory element was edited out using the clustered regularly interspaced short 
palindromic repeats (CRISPR)-Cas9 system in B16-BL6 cells as shown in Fig. 3.9A. The 
two guide RNA sequences with the protospacer adjacent motif (PAM; 3 bases 
highlighted in red) in the 3’-ends were designed to be complimentary to genomic regions 
upstream and downstream of the putative enhancer. Cas9-mediated cleavage of the DNA 
was expected to yield two blunt ends that would be repaired via the non-homologous end 
joining (NHEJ) pathway. To confirm that the genome has been edited, the forward primer 
(Fig. 3.9A: red arrow), which is complimentary to the sequences of the 5’-side of the 
genomic NHEJ product, was used in combination with either the 11780 (inner) or 5794 
(outer) reverse primers that target the un-edited or edited 3’-side of the genomic NHEJ 
products, respectively. The amplicons produced by the inner primer set (241 bps) 
indicates failure to generate DNA double strand breaks and intact enhancer region, 
whereas amplicons produced by the outer primer set (296 bps) infers successful knock-
out of the enhancer and repairing of the genome. I initially analyzed the PCR products 
using these primer sets in wild-type and B16-BL6 cells transfected with two different 
amounts (1 and 1.5 µg; herein termed CR1 and CR1.5) of the CRISPR editing plasmids. I 
found that only the inner amplicons were detected in non-transfected wild-type cells (Fig. 
3.9B), which was an expected finding as the genomic region that spans the enhancer 
targeted by the outer primer set is too large to be amplified under the same PCR 
conditions (6229 bps). In contrast, both of the inner and outer primer sets yielded 
amplicons with expected sizes in cells transfected with the CRISPR editing plasmids 
(Fig. 3.9B). These results indicated that the gene-edited cells were likely heterogeneous 
cell populations that consisted of cells harboring the genomic sequences of the edited and 
un-edited regulatory element. Therefore, I selected 9 single colonies from these cells and 
re-analyzed for the enhancer knock-out. Among them, one colony (#4) showed PCR 
products from both inner and outer primers while only PCR products from the inner 
primers were detected in all of the other colonies (Fig. 3.9C). To further examine if 
colony #4 originated from a single cell, cells were sub-cloned and re-analyzed for the 
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genome edition status. PCR amplicons from the inner and outer primers were detected in 
all the 8 sub-colonies examined (Fig. 3.9D), suggesting that the colony contains a 
homogenous cell population harboring only one allele with successful gene editing. 
3.2.3.1 Monoallelic deletion of the putative regulatory element 
compromises the production of IL-1β eRNAs and mRNA 
To examine the role of the putative regulatory element in eRNA and IL-1β mRNA 
production, cells harboring the monoallelic regulatory element and wild-type cells were 
transfected with PU.1 for 48 h, then stimulated with LPS for 6 h. Cells with the 
monoallelic regulatory element produced significantly lower amount of eRNAs than cells 
with intact regulatory element based on qPCR assays using the 11743, 10841, 10368, and 
9486 primer sets (Fig. 3.10A). In line with these results, expression of IL-1β mRNA was 
significantly reduced by ~70% in cells with monoallelic regulatory element than control 
cells (Fig. 3.10B).  
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Figure 3.9. Genetic deletion of the putative regulatory element by a CRISPR-Cas9 
vector in B16-BL6 cells. A) Visual representation of the relative locations of CRISPR-
Cas9-mediated cleavage sites, and primer sets used to validate the deletion of the 
enhancer region in B16-BL6 cells. PCR products of 241 and 296 bp sizes using the 
combination of the forward primer (12001: red arrow) and the inner (11780: black arrow) 
or the outer (5794: black arrow) reverse primers suggest unsuccessful and successful 
deletion of the putative regulatory element, respectively. The sequences 5’-
AAATGCCAGCGCCCTGAGAG-3’ and 3’-AGGCAAATTCAATGGGAATG-5’ are 
complimentary to the gRNAs used, and the 3 bp DNA sequences highlighted in red 
indicate the PAM sequence. B) The PCR products amplified by the inner and outer 
primer sets were analyzed in wild-type and B16-BL6 cells transfected with CRISPR 
editing plasmids (1, 1.5 µg). Detection of bands for inner primer and outer primer sets 
indicate the presence or absence of the putative regulatory element, respectively. C and 
D) Gel electrophoresis analyses of the PCR amplicons from CR1(C)- and colony #4(D)-
derived single colonies. Identical validation system described in (A) and used in (B) were 
employed to confirm the success of genome edition. 
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Figure 3.10. Monoallelic deletion of the putative regulatory element compromises 
the productions of eRNAs and IL-1β mRNA. A and B) PU.1 (0.7 µg) was transfected 
in wild-type and B16-BL6 cells with the monoallelic regulatory element with the 
transfection reagent Polyjet for 48 hours, then stimulated with LPS (100 ng/mL) for 6 
hours. Cells were harvested and cDNA was prepared with RT-PCR. The qPCR amplicons 
of the eRNAs (A) using 11743, 10841, 10368, and 9486 primer sets and IL-1β mRNA 
(B) were analyzed. Data are expressed as means ± S.D. (n=3); *,p < 0.05,**,p < 0.05, 
****,p < 0.05, Student’s t test.  
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3.2.4 Knocking-down the putative eRNA suppresses IL-1β mRNA 
expression 
To further examine the role of the eRNA produced in B16-BL6 cells, I first knocked 
down the eRNA using the ASO as described in Section 3.1.4. In line with previous 
results, LPS stimulation induced eRNA transcription by approximately 5-20 fold in PU.1-
overexpressing B16-BL6 cells, and eRNA-ASO suppressed the production of eRNAs 
based on primer sets 10841, 10368, and 9486 by approximately 71%, 76.5%, and 76%, 
respectively (Fig. 3.11A). Also, IL-1β mRNA production in LPS-stimulated cells with 
the eRNA knocked-down was almost fully abolished (Fig. 3.11B), suggesting that the 
eRNAs also play a critical role in IL-1β mRNA expression in B16-BL6 cells expressing 
PU.1. 
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Figure 3.11. eRNAs regulate LPS-induced IL-1β response in PU.1-overexpressed 
melanoma cells. A and B) B16-BL6 cells were overexpressed with PU.1 (0.7 µg) for 48 
hours, then re-transfected with scrambled- or eRNA-ASO (250 pmole) for 24 hours. 
Upon completion of transfection, PU.1-overexpressed B16-BL6 cells were exposed to 
LPS (100 ng/mL) for 6 hours. Expression levels of eRNAs (A) and IL-1β mRNA (B) 
were analyzed by qPCR. Data are expressed as means ± S.D. (n=3); *, P < 0.05, **, P < 
0.05, ***, P < 0.05, Student’s t test. 
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3.2.5 PU.1 orchestrates the interaction between the putative IL-1β 
regulatory element (enhancer) and promoter independent of 
stimulatory signal 
We identified that our proposed genomic region serves as an enhancer of IL-1β by 
examining the characteristics that are required to define an enhancer. Specifically, PU.1-
dependent activation of the enhancer induces the production of eRNAs, which contribute 
in the regulation of IL-1β. The ability of PU.1 to control the expression level of IL-1β 
piqued our interest in other potential methods of gene regulation. Hence, enhancer-
promoter interactions were measured via 3C-TaqMan qPCR analysis to determine 
whether or not local chromatin landscape of IL-1β is altered as a consequence of PU.1 
overexpression. To begin with, Fig. 3.12A shows that we detected basal level ligation 
between proximal fragments and the promoter of IL-1β in wild-type B16-BL6 cells, 
which likely occurred due to chance. Interestingly, we were also able to detect the 
interaction between the IL-1β promoter with a fragment ~15 kbs away, indicating that 
these regions are closely situated in the nuclear space. We then explored the role of PU.1 
in promoting the formation of enhancer-promoter interactions (Fig. 3.12B). It is 
noteworthy that diagrams for LDTF-overexpressed cells only displays additional 
interactions that we detected on top of the interactions that occurred in the wild-type 
cells. Dissimilar to the case in wild-type melanoma cells, abundance of PU.1 induced 
chromatin looping between the enhancer and the promoter. Like macrophages, LPS 
stimulation of PU.1-overexpressed cells also enhanced the ligation frequency between the 
regulatory elements (Fig. 3.12C), suggesting that re-organization of the chromatin 
landscape is stimulus-dependent. Furthermore, ectopic expression of C/EBPα in B16-
BL6 cells caused minimal ligation between the enhancer and the promoter (Fig. 3.12D). 
Since C/EBPα is not involved in promoting the generation of IL-1β mRNA and eRNAs, 
we speculated that the chromatin structure between unstimulated and stimulated C/EBPα-
overexpressed cells would not differ; thus, 3C sample of stimulated cells was omitted and 
not prepared.  
Next, we also quantitatively analyzed the effect of LPS treatment in promoting the 
interaction between the enhancer and the promoter in B16-BL6 cells overexpressed with 
both LDTFs. In agreement with cells that were solely transfected with PU.1, concomitant 
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expression of PU.1 and C/EBPα caused greater number of enhancer fragments to 
associate with the promoter of IL-1β upon LPS exposure (Fig. 3.12E, F). Finally, we 
examined the interaction between the regulatory elements in our CRISPR cell line (PU.1-
overexpressed) with partial knock-out of the enhancer region. Although we expected 
reduced occurrence of enhancer-promoter interactions in CRISPR cells, we were still able 
to observe that the intact enhancer region physically associated with the IL-1β promoter 
via PU.1-mediated chromatin re-organization (Fig. 3.12G). 
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Figure 3.12. Overexpression of PU.1 induces physical interaction between the IL-1β 
enhancer and promoter. A-G) 3C-Taqman qPCR using the same combinations of 
primers as described in Fig. 3.6 was used to examine the enhancer-promoter interaction 
frequencies in wild-type, LDTF-overexpressing, and genome edited B16-BL6 cells. 
Wild-type B16-BL6 melanoma cells (A), cells that were transfected with PU.1 and/or 
C/EBPα (0.7 µg each; B-F), and cells with monoallelic regulatory element transfected 
with PU.1 (0.7 µg; G) were either unstimulated or stimulated with LPS (100 ng/mL) for 6 
hours. The cells were harvested, underwent formaldehyde crosslinking, and lysed. The 
extracted nuclei were digested with 400 U of DpnII for 24 hours and subsequently ligated 
for 72 hours. The overarching arrows in (B-G) represent additional interactions between 
fragments with the IL-1β promoter that were detected on top of the background 
interactions shown in wild-type B16-BL6 cells (A). The bars in each diagram represent 
the frequencies of interaction between the promoter region targeted by the universal 
forward primer and any DNA regions that localize with the promoter in the nuclear 
space. 
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3.3 Elucidating the role of PU.1 domains in the IL-1β regulatory 
network 
3.3.1 Examining the role of PU.1 domains in IL-1β eRNA and mRNA 
expression 
It has been shown that PU.1 has four distinct domains: acidic, Gln-rich, PEST, and Ets 
(DNA binding) [99,135]. Fig. 3.13A illustrates the locations of these domains and 
constructs of PU.1 mutant plasmids obtained from Dr. Dekoter at UWO. To examine the 
role of each domain, wild-type PU.1 and its mutants were transfected in B16-BL6 cells, 
and production of IL-1β mRNA and the putative eRNA were analyzed. Cells transfected 
with PU.1 mutant plasmids lacking either the acidic (Δ2-30, Δ33-74) or the Gln-rich 
(Δ75-100) domain or with the mutated Ets domain (PU.1R230, 233A: 230th and 233rd 
arginine residues have been replaced with alanine) failed to produce IL-1β mRNA in 
response to LPS, whereas cells transfected with the mutant lacking the PEST domain 
(Δ118-167) produced IL-1β mRNA to the same extent as cells transfected with wild-type 
PU.1 (Fig. 3.13B). Although changes in eRNA production was not as drastic as those of 
mRNA, a similar trend was observed where the levels of eRNA expression induced 
remained consistent in cells transfected with PU.1WT and PU.1Δ118-167, but the levels were 
substantially reduced in cells transfected with PU.1Δ2-30, PU.1Δ33-74 , PU.1Δ75-100 and 
PU.1R230, 233A (Fig. 3.13C). These results suggest that the acidic, Gln-rich and Ets 
domains of PU.1 are required by the cells to generate IL-1β in response to LPS. 
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Figure 3.13. LPS-induced production of IL-1β is dependent on the acidic, Gln-rich, 
and Ets domains of PU.1. A) A schematic of PU.1 domains and the constructs of PU.1 
mutant plasmids. Domains are represented by each coloured block; acidic (blue), Gln-
rich (green), PEST (yellow), and Ets (red). B and C) B16-BL6 cells were transfected with 
PU.1 WT (1 µg) or PU.1 mutant (PU.1Δ2-30, PU.1Δ33-74 , PU.1Δ75-100, PU.1Δ100, PU.1Δ118-167, 
PU.1R230, 233A) plasmids for 48 hours, then stimulated with LPS (100 ng/mL) for 6 hours. 
The production of IL-1β mRNA (A) and eRNAs (B) were analyzed by qPCR. Data are 
expressed as means ± S.D. (n=2); *, P < 0.05, **, P < 0.05, ***, P < 0.05 ANOVA. 
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3.3.2 Examining the involvement of PU.1 domains in the IL-1β 
enhancer-promoter interaction 
In section 3.2.5, I showed that overexpression of PU.1 promoted the interaction between 
the enhancer and the promoter. To further examine the involvement of each PU.1 domain 
in the IL-1β enhancer-promoter interaction, B16-BL6 cells were transfected with wild-
type and various mutants (PU.1Δ33-74, PU.1Δ75-100, PU.1Δ100, PU.1Δ118-167, and PU.1R230, 233A) 
of PU.1. The interaction between the enhancer and the promoter in the reprogrammed 
B16-BL6 cells was analyzed via 3C-TaqMan qPCR only using the primers that target the 
five fragments within the putative enhancer. Expectedly, overexpression of PU.1WT in 
B16-BL6 cells restructured the genome to cause the enhancer and the promoter of IL-1β 
to interact (Fig. 3.14A). Similar to PU.1WT-transfected cells, the enhancer-promoter 
interaction in melanoma cells ectopically expressed with PU.1 mutants remained intact 
(Fig. 3.14B-F), as majority of the fragments that spanned the enhancer ligated with the 
IL-1β promoter. Although only the PU.1Δ118-167 mutant induced the IL-1β eRNA and 
mRNA (Fig. 3.13) while all other PU.1 mutants were unable to do so, the extent of the 
enhancer-promoter interaction in PU.1Δ33-74-, PU.1Δ75-100-, and PU.1Δ118-167-overexpressed 
cells did not change when compared to that of cells transfected with wild-type PU.1 (Fig. 
3.14B, C, E). Interestingly, simultaneous knock-out of the acidic and Gln-rich domains 
(PU.1Δ100) resulted in decreased enhancer-promoter interaction frequency. These data 
suggest that both the acidic and Gln-rich domains of PU.1 act in concert to reorganize the 
chromatin while the PEST domain is dispensable for the enhancer-promoter interaction. 
Similar to the PU.1Δ100 mutant, mutation in the DNA binding domain (PU.1R230, 233A) also 
disrupted the interaction between the regulatory elements; which was an expected 
finding, as such mutation can inhibit PU.1 binding to the DNA. Furthermore, in order to 
compare the enhancer-promoter interaction frequencies between samples from Fig. 3.14, 
the ligation frequencies between individual fragments in the putative enhancer with the 
IL-1β promoter were summed. As illustrated in Fig. 3.14G, the interaction between the 
enhancer and the promoter of IL-1β were significantly reduced in melanoma cells 
ectopically expressed with PU.1Δ100 and PU.1R230, 233A; indicating that not only do 
acidic/Gln-rich and DNA binding domains have roles in gene transactivation and DNA 
binding capacity of PU.1, respectively, but also partake in chromatin organization. 
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Figure 3.14. The acidic, Gln-rich, and DNA binding domains of PU.1 mediate IL-1β 
enhancer-promoter interaction. A-F) PU.1 (A) or PU.1 mutant (domains deleted: 
acidic – B, Gln-rich – C, acidic & Gln-rich – D, PEST – E, domain mutated: DNA 
binding – F) was overexpressed in B16-BL6 melanoma cells. Upon completion of the 48 
hour transfection period, 3C library was prepared from cells that underwent a cycle of 
crosslinking, restriction enzyme digestion (400 U DpnII) and ligation. The physical 
association of the enhancer and the promoter was quantified via TaqMan qPCR. The 
black arrows in (A-F) represent the occurrence of ligation between fragments positioned 
within the putative enhancer with the IL-1β promoter. The upright grey bars in each 
diagram represent the frequencies of interaction between the promoter region and the 
distal enhancer fragments. G) The quantitative values of ligation frequencies represented 
as bars in (A-F) were totaled and compared. The ligation frequency between the enhancer 
and the promoter of IL-1β in B16-BL6 cells overexpressed with wild-type PU.1 was used 
as the control. Data are expressed as means ± S.D. (n=2); *, P < 0.05, **, P < 0.05, 
ANOVA. 
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Chapter 4 
4 Discussion 
In this study, I proposed that the genomic region located ~10 kbs upstream of the IL-1β 
TSS is an enhancer regulating the expression of IL-1β, based on histone modification 
markers: H3K27Achi, H3K4me1hi, and H3K4me3low (Fig. 3.1). It has been suggested that 
eRNAs are dynamically transcribed as a consequence of enhancer activation [136]. 
Therefore, I first examined whether the genomic region produced eRNAs in response to 
LPS in RAW264.7 cells (Fig. 3.2B, C). Upon LPS treatment, eRNA(s) was rapidly 
generated and reached a peak level in 90 mins, which was earlier than that of IL-1β 
mRNA that reached maximal production at 180 mins post LPS stimulation (Fig. 3.2D). 
These results were consistent with previous studies showing that transcription of 
enhancers precede production of mRNAs [137-139]. Specifically, de Santa et al. 
demonstrated that transcripts generated from genomic regions with enhancer-specific 
chromatin signatures (H3K4me1hi and H3K4me3low) upstream of the chemokines, 
chemokine ligand 5 (Ccl5) and C-X-C motif chemokine 11 (Cxcl11), were detected at an 
earlier time point than mRNAs in LPS-stimulated macrophages [138]. They employed 
ChIP-seq to show that the production of these transcripts was the result of LPS-induced 
binding of Ser5P (phosphorylated Serine 5 of CTD) RNAPII at the genomic regions 
[138]. Furthermore, another study demonstrated that transcription of enhancers preceded 
their proximal promoters in various cell types including stem cells, differentiating 
committed progenitor cells, and terminally differentiated primary cells [137]; suggesting 
that early transcription of eRNAs is a general phenomenon and can be a necessity for 
upregulation of target genes. Thus, the rapid production of the putative eRNA before the 
advent of IL-1β mRNA may suggest a role of the eRNA in IL-1β mRNA expression. I 
examined the role of the putative eRNA in IL-1β mRNA expression using the anti-sense 
eRNA targeting ASO (Fig. 3.4). Through successful knock-down of the eRNA, the 
expression of IL-1β mRNA was also suppressed; inferring that the eRNA is not just a by-
product of enhancer transcription, but is a functionally important molecule involved in 
the regulation of IL-1β. My results were in line with several other studies that also 
showed that suppression of eRNAs by short hairpin (sh) RNA, siRNA, and ASO reduced 
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their cognate gene transcription [80,140,141]. In particular, Lam et al. demonstrated that 
the expression levels of matrix metallopeptidase 9 (Mmp9) and CX3C chemokine 
receptor 1 (Cx3cr1) genes were attenuated upon ASO-mediated inhibition of Mmp9 and 
Cx3cr1 eRNAs, respectively, in BMDMs [115]. Furthermore, they engineered a reporter 
plasmid that comprised the Mmp9 enhancer upstream of the Mmp9 promoter, which 
controlled the Luc expression [115]. When the sequence of the sense eRNA was removed 
from the Mmp9 enhancer, Lam et al. reported that the Luc expression decreased, whereas 
the presence or the absence of the antisense eRNA sequence did not affect the activity of 
the Mmp9 promoter [115]; concluding that the Mmp9 enhancer regulates the transcription 
of Mmp9 gene via eRNAs in a strand- and orientation-dependent manner. Considering 
that eRNAs can be transcribed bi-directionally, knock-down of the sense eRNA 
transcribed from the IL-1β enhancer can address whether or not eRNA-mediated 
regulation of IL-1β is orientation-specific. Moreover, through ddPCR experiments I 
showed that high levels of eRNA production were detected in the central region (between 
primer sets 8453-10841) of the enhancer (Fig. 3.3B). In addition, eRNA detected by 9013 
and 11743 primer sets did not increase to the same extent as shown in the qPCR data, 
suggesting that the actual eRNA produced from the putative regulatory element could be 
an uni-directional long non-coding RNA approximately 2500 bps in size. However, this 
speculation is inconsistent with the current notion that the median length of eRNAs is 
~350 bps [94]. Not only that, ChIP-seq analysis of RNAPII in Fig. 3.1 illustrates that 
RNAPII is dispersed (mainly enriched at two distinct regions) within the H3K27Ac-
enriched enhancer region. Taking into account that LPS exposure of macrophages 
resulted in the enrichment of Ser5P RNAPII at enhancers, it is highly probable that the 
pre-docked RNAPII at the enhancer are paused, which are eventually converted into the 
elongation phase upon cell activation. Therefore, I surmise that the transcripts generated 
from the enhancer are not uni-directional, but are rather bi-directional transcripts that 
vary in size and orientation (sense and antisense). 
Another checkpoint that needed to be fulfilled in order to label the proposed genomic 
region as an enhancer was that the distal enhancer and the promoter must be in the 
vicinity of one another irrespective of any intervening DNA [129,142,143]. Here, I found 
that the local chromatin landscape of IL-1β was altered, and the enhancer-promoter 
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interaction was established in a stimulus (LPS)-dependent manner in macrophages (Fig. 
3.6C). This observation is in line with a previous study that demonstrated the 
communication between the IL-1β promoter with another potential enhancer (~3 kbs 
upstream of TSS) in LPS-exposed macrophages [144], suggesting that an extracellular 
stimulus is required and necessary to remodel the chromatin architecture of IL-1β. 
Despite the fact that low levels of IL-1β are constitutively expressed in macrophages, 
remodeling of the chromatin architecture, which brings distal regulatory elements into 
proximity, is absolutely necessary for rapid induction of IL-1β. There are multiple factors 
that are involved in the formation of enhancer-promoter interactions. For example, Lai et 
al. reported that shRNA-mediated knock-down of MED1 and MED12 subunits abolished 
the interaction between the zinc finger protein SNAI1 gene and its enhancer in HEK293 
cells [110]. Another group has highlighted the role of cohesin in establishing enhancer-
promoter interactions by depleting the cohesin subunit, double-strand-break repair protein 
(RAD21), in MCF-7 cells stimulated with 17β oestradiol; essentially abrogating the 
interaction between the regulatory elements of the nuclear receptor-interacting protein 1 
(NRIP1) gene [80]. Intriguingly, the mediator complex and cohesin tend to co-occupy 
enhancers and promoters, and it has been shown that the recruitment of these protein 
complexes is mediated by eRNAs [80,110,119]. In this study, I saw a correlation between 
the enhancer-promoter ligation frequency and eRNA production in LPS-stimulated 
macrophages, potentiating the role of eRNAs in remodeling the chromatin landscape of 
IL-1β via recruitment of the Mediator complex and cohesin.  
It is generally believed that a cell-type specific repertoire of enhancers is chosen by 
various LDTFs [145]. It has been shown that nucleosome depletion and subsequent 
recruitment of LDTFs to putative enhancers are events that occur prior to the deposition 
of unique chromatin signatures like H3K4me1hi and H3K4me3low [145,146]. Specifically, 
PU.1 is a LDTF that has the ability to select macrophage-specific enhancers [146], which 
induce the upregulation of genes essential for macrophage differentiation and function. 
Previously, it was shown that overexpression of PU.1 and C/EBPα transdifferentiated the 
NIH 3T3 murine fibroblast cells into macrophage-like cells that displayed macrophage 
morphology, and acquired the ability to produce cytokines and phagocytose bacteria 
[147]. This led me to hypothesize that enhancers of IL-1β are recognized and activated by 
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PU.1. In order to determine whether or not activation of the enhancer is PU.1-dependent, 
I took an alternative approach and used non-myeloid B16-BL6 cells that do not produce 
IL-1β mRNA but respond to LPS (Appendix A, Fig. 3.7B). I found that ectopic 
expression of PU.1 in the B16-BL6 cells induced eRNA and IL-1β mRNA transcription 
upon exposure to LPS (Fig. 3.8B, 3.7B). Additionally, through CRISPR-Cas9-mediated 
knock-out of the enhancer followed by PU.1 overexpression, I observed reduced 
expression of eRNAs and IL-1β mRNA (Fig. 3.10), suggesting that the genomic region 
serves as the enhancer of IL-1β. Moreover, ASO-mediated knock-down of the eRNA 
inhibited IL-1β expression (Fig. 3.11). These results indicate that PU.1, which drives 
macrophage differentiation at high concentrations [102], recognized and opened up the 
macrophage-specific IL-1β enhancer in B16-BL6 cells. It has been reported that PU.1 
promotes the deposition of H3K4me1 and recruitment of p300 at enhancers in 
macrophages [103,104]. Furthermore, stimulation of macrophages induces the binding of 
p65 (active subunit of NF-κB) at PU.1/p300 co-occupied, and H3K4me1-enriched 
enhancer regions [65]; suggesting that LPS-induced production of eRNAs in PU.1-
overexpressed B16-BL6 cells is the result of these sequence of intracellular events. 
Conversely, C/EBPα had minimal impact on the production of both transcripts, which is 
expected as abundance of C/EBPα is associated with the development of granulocytes 
and neutrophils [107,108]. However, the role of C/EBPα should not be neglected as low 
level of endogenous C/EBPα mRNA was detected in B16-BL6 cells (data not shown). 
Since majority of macrophage-specific enhancers tend to be co-occupied by PU.1 and 
C/EBP family of proteins [86,148,149], which recruit p65 most efficiently [129], it is 
likely that both LDTFs are required for the activation of the IL-1β enhancer.  
Moreover, I utilized 3C analysis to investigate the role of LDTFs in reorganizing the 
chromatin landscape, specifically resulting in the formation of IL-1β enhancer-promoter 
interactions, whether it be solely under the influence of PU.1, C/EBPα or the combination 
of the two LDTFs. It has previously been shown that PU.1 has the capacity to remodel 
the chromatin architecture and mediate enhancer-promoter interactions [130,150]. For 
example, PU.1 is able to autoregulate itself by binding to a distal enhancer (~14 kbs 
upstream of the PU.1 TSS) and bridging its physical association with the PU.1 promoter 
in hematopoietic stem cells and macrophages [150]. Likewise, as presented in Fig. 3.12B, 
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I found that the physical association of the IL-1β enhancer and promoter occurred upon 
ectopic expression of PU.1 in B16-BL6 cells. The PU.1-dependent association of the 
regulatory elements was absent in RAW264.7 macrophages, indicating that higher 
concentration of PU.1 may be required for the enhancer-promoter interaction to be pre-
formed. Furthermore, C/EBPα also had the capacity to bridge the interaction between the 
enhancer and the promoter (Fig. 3.12D), which was an unexpected finding because this 
TF did not render the B16-BL6 cells to express IL-1β (Fig. 3.7B). Enhancer-promoter 
interactions in C/EBPα-overexpressed cells could have emerged due to low levels 
endogenous PU.1 in the cells, which could be generated by C/EBPα-mediated activation 
of the PU.1 promoter and distal enhancer [151,152]. These results indicate that both 
LDTFs, whether directly or indirectly, partake in the formation of enhancer-promoter 
interactions prior to LPS challenge. Moreover, similar to macrophages, LPS stimulation 
of the reprogrammed melanoma cells increased the interaction frequency between the IL-
1β regulatory elements. This observation signifies that the the enhancer-promoter 
interaction in the IL-1β regulatory network is stimulus-dependent, and supports the 
potential involvement of eRNAs is mediating the communication between the regulatory 
elements. 
PU.1 is a 271 amino acid long protein with four distinct domains.  Since PU.1 is deemed 
the master regulator of IL-1β transcription in the reprogrammed B16-BL6 cells, I was 
interested in examining the role of each PU.1 domain in promoting the expression of IL-
1β eRNAs and mRNA, as well as enhancer-promoter interactions. As the PU.1 mutants 
had contrasting effects on the overall production of IL-1β mRNA and eRNAs (Fig. 
3.13B, C), we predicted that the frequency of enhancer-promoter interactions 
orchestrated by these PU.1 variants would also differ. To our surprise, there was no 
significant change in how frequently the regulatory elements of IL-1β ligated in cells 
overexpressed with the PU.1 variants, despite complete abrogation of IL-1β mRNA and 
eRNAs in PU.1Δ33-74- and PU.1Δ75-100-transfected cells (Fig. 3.14). Most interestingly, 
concomitant knock-out of the acidic and Gln-rich domains of PU.1 (PU.1Δ100) attenuated 
the interaction between the enhancer and the promoter of IL-1β. Thus, these findings lead 
to the conclusion that single domains of PU.1 are not responsible for the establishment of 
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chromatin looping between the enhancer and the promoter, but are dictated by the 
cooperation of two domains in the N-terminus of PU.1. Reorganization of the chromatin 
landscape mediated by the acidic and Gln-rich domains could potentially be an 
underlying mechanism of their ability to transactivate genes. Furthermore, there are other 
potential candidates that could collaborate with PU.1 to rearrange the chromatin. The first 
group of candidates is HATs such as CBP and p300, which directly interact with the Gln-
rich domain of PU.1 [153,154]. Although the role of HATs in enhancer-promoter 
interactions has not yet been demonstrated, they are transcription co-factors that co-
localize with pioneer factors and acetylate unique residues of histones [47,81]. 
Specifically, Whalen et al. exemplified the enrichment of H3K27Ac at interacting 
regulatory elements [155], which extends the possibility that the proteins responsible for 
the deposition of such chromatin signature may be essential for the interaction to occur. 
Brd4, a protein that contains 2 bromodomains, is the other candidate that could bring the 
regulatory elements into vicinity. It has been postulated that Brd4 binds enhancers (co-
occupied by PU.1) and promoters to promote transcription [156,157]. The Brd-4-specific 
inhibitor, JQ1, could be used to suppress Brd-4 mediated generation of the putative 
eRNA to study its role in chromatin remodeling. Lastly, it has been demonstrated that 
5hmC, the oxidized metabolite of 5mC, accumulates at enhancers and is associated with 
enhancer activity [158,159]. Hon et al. has previously shown that Tet2-mediated 
conversion of 5mC to 5hmC at enhancers correlated with binding of various TFs such as 
Oct4 and Sox2 in mouse embryonic stem cells [158]. Interestingly, PU.1 is able to 
physically interact and recruit Tet2, possibly suggesting that hypomethylated state of 
regulatory elements may contribute in chromatin reorganization [160]. 
In summary, I identified an enhancer of IL-1β that lies ~10 kbs upstream of the TSS. This 
particular enhancer was activated by PU.1, which serves as the pioneer transcription 
factor that recruits other necessary components to initiate transcription of the putative 
eRNA in response to LPS stimulation. Most notably, in the presence of abundant PU.1, 
intra-chromosomal interaction between the enhancer and the promoter was formed, 
which was further enhanced upon stimulation of the cells with LPS. Fig. 4.1 illustrates 
my working model of PU.1 and IL-1β enhancer-promoter looping formation. This study 
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unraveled the mechanisms by which PU.1 regulates the expression of IL-1β in response 
to LPS stimulation. 
4.1 Clinical significance and therapeutic treatment 
The concept of chromatin architecture has recently garnered attention as it adds a layer of 
complexity in gene regulation. Thorough analysis of how the chromatins are organized 
can be used to define the overall state or identity of cells. For example, taking into 
account that a repertoire of enhancers is cell-type specific, malignant cells with unique 
gene expression profiles will display enhanced physical association between the 
regulatory elements of highly active genes; thus, our knowledge of chromatin architecture 
can be considered as a preventive measure. This is also applicable in our attempt to 
regulate the expression of IL-1β. In many IL-1β-induced diseases, we can analyze 
whether or not the uncontrolled expression of the cytokine is caused by high interaction 
frequency between our proposed enhancer and the promoter. If so, considering that 
eRNAs are one of the determinants of enhancer-promoter interactions [80,110,111], 
sequence-specific ASO can be employed to target the eRNAs and disrupt their activity. 
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Figure 4.1. Schematic representation of how the IL-1β regulatory network is 
modulated by PU.1. Enhancer-promoter interactions are pre-formed at high 
concentrations of PU.1. PU.1 has an additional role of recruiting p300/CBP and Tet that 
can deposit epigenetic marks such as H3K27Ac and 5hmC on histones and cytosine, 
respectively. Acetylated lysines of histone H3 are recognized by Brd4, which activates P-
TEFb to initiate transcription of IL-1β eRNA and mRNA. 
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4.2 Future studies 
4.2.1 Identifying other active enhancers of IL-1β via 3C-derivative 
experiments 
It is widely accepted that multiple enhancers work in concert to trigger transcription of 
genes. However, the ability of enhancers to function over long distances makes it 
challenging for investigators to pinpoint their cognate genes. This study used 3C-TaqMan 
qPCR to quantitatively analyze the physical association between the IL-1β enhancer and 
promoter. A disadvantage of 3C analysis is that only known sequences of the captured 
fragment (enhancer) and the bait (promoter) are examined [161]; thus, this particular 
technique cannot be utilized for genome-wide studies. In order to overcome the limit, 3C-
derivative experiments such as 4C (3C-seq; 3C followed by next generation sequencing) 
has gained popularity in recent years. Therefore, 3C is often described as a one-to-one 
approach and 4C is a one-to-all approach [162]. In contrast to using a single 4-cutter 
restriction enzyme in 3C, two rounds of digestion are performed in 4C [163]. The 
primary digestion step, which involves digestion of the crosslinked DNA with a 6-cutter 
restriction enzyme and a subsequent ligation step, is followed by a secondary 
digestion/ligation step to generate small circular DNA [162,163]. The ligated captured-
bait fragments are then amplified with bait-specific primers via PCR, and the resulting 
products are sequenced through NGS [162,163]. Our lab has performed 4C analysis using 
IL-1β promoter as the bait and identified 5 other genomic locations that formed intra-
chromosomal interactions (Appendix B). These interactions now can be confirmed by 3C 
analysis or reverse 4C (using the candidate enhancers as the bait). 
4.2.2 Elucidating the role of epigenetic modifiers in IL-1β regulation 
The level of histone acetylation is determined by the interplay between HATs and 
HDACs [164-166]. Histone acetylation initiates depletion of nucleosomes, rendering 
DNA accessibility to various transcription factors [167]. For example, Frank et al. 
showed that inhibition of HDACs results in remarkable changes in chromatin 
accessibility and PU.1 preferentially associated with euchromatin [168]. Although the 
dynamic switch from euchromatin to heterochromatin is dictated by HDACs, the ability 
of these histone modifiers to remodel the chromatin architecture on a genome-wide scale 
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has not yet been determined. Our lab showed that HDAC8, a member of class I HDACs, 
selectively deacetylates H3K27Ac [169]. In addition, the diminished levels of H3K27Ac 
are in line with reduced eRNA and IL-1β mRNA production [169]. Considering that 
H3K27Ac is a unique marker of active enhancers, I speculate that the mechanism of 
HDAC8 in regulating IL-1β expression is likely through enhancing the enhancer-
promoter interaction. Since I identified the IL-1β enhancer, it will be interesting to 
examine whether HDAC8 is involved in the enhancer-promoter interaction through 3C 
analysis in macrophages. We expect that overexpression of HDAC8 will abolish the 
enhancer-promoter interaction; whereas, HDAC8 inhibition will result in higher 
frequency of the interaction. 
4.2.3 Examining the mechanism of macrophage tolerance 
As previously mentioned, plasticity and heterogeneity are hallmarks of macrophages. 
Tissue-resident macrophages are scattered throughout the body, and have the capacity to 
generate appropriate responses according to the environmental cues [170,171]. Amongst 
many stimuli that foster cell-type specific responses, prolonged exposure to LPS can 
result in the development of a phenomenon known as LPS tolerance [172,173]. In this 
hyporesponsive state, macrophages become refractory to a secondary LPS challenge 
[173,174]. Another notable environmental stimulus that suppresses macrophage 
activation is the probiotic strain such as Lactobacillus rhamnosus GR-1 [175]. Similar to 
LPS-tolerated macrophages, pre-exposure of macrophages to L. rhamnosus GR-1 
abrogated expression of IL-1β. Granulocyte colony stimulating factor (G-CSF), which is 
well-known for its involvement in the generation of neutrophils, is an immunoregulatory 
cytokine that leads macrophages to immunomodulatory cells [176,177]. Contrastingly, 
recent discoveries documented that macrophages can be converted into nonspecific innate 
memory cells upon initial exposure to β-glucan [178]. In this trained state, macrophages 
have acquired the ability to generate a stronger response to secondary stimuli [178,179]. 
Interestingly, increased responsiveness of trained macrophages is the product of elevated 
H3K27Ac and H3K4me3 levels at distal enhancers and promoters, respectively 
[178,180]. Epigenetic reprogramming of innate memory cells raises the possibility that 
macrophage tolerance is regulated via similar epigenetic mechanisms. Furthermore, such 
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phenotypic variance of macrophages prompts us to investigate if different activity states, 
particularly in regards to IL-1β production, are affected by enhancer-promoter 
interactions; which can be determined through 3C-Taqman qPCR. We speculate that 
macrophage training is largely associated with enhanced interaction between the 
regulatory elements while LPS-, GR-1-, and G-CSF-mediated tolerance will show 
opposing results. These findings could be directly linked to epigenetic reprogramming of 
the genome, and various histone modifiers can be targeted to modulate chromatin 
reorganization.  
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Appendices 
Appendix A: LPS-stimulation induces activation of MAPKs in wild-type and PU.1-, 
C/EBPα-overexpressed B16-BL6 cells. Expression levels of phospho-p38, phospho-
ERK, and phospho-IκB in wild-type and PU.1-, C/EBPα-overexpressed (transfected 0.7 
µg of each plasmid with Polyjet for 48 hours) B16-BL6 cells untreated or treated with 
LPS (100 ng/mL) for 1, 2, or 3 hours were analyzed by Western blots. Β-actin was used 
for loading controls. Data in Appendix A were generated by Dr. Soon-Duck Ha. 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phospo-ERK
0    1   2    3   0    1   2   3   h, LPS (100 ng/mL)
VC PU.1/CEBPα
Phospo-p38
β-actin
Phospo-IkB
111 
 
Appendix B: 4C analysis of inter- and intra-chromosomal interactions between the 
IL-1β promoter and potential enhancers scattered in the genome. A) Circos plot 
displays physical association of the IL-1β promoter with enhancers localized in different 
chromosomes of activated macrophages. LPS-stimulated RAW264.7 macrophages were 
harvested and crosslinked with formaldehyde. Two cycles of restriction enzyme digestion 
and ligation were performed in 4C. The extracted DNA was sequenced with Illumina 
sequencing. B) Computational analysis of the raw sequencing data also generated a 
spider plot to display the intra-chromosomal interactions detected in activated 
macrophages. Data in Appendix B were generated by Dr. Soon-Duck Ha and Jeremy 
Wong. 
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